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Introduction 
 This capstone report includes three manuscripts, focused on adolescents in regards to 
prescribing practices, risk behaviors correlated with depressive symptoms, and risk behavior in a 
primary health clinic.  The first manuscript presents a critical analysis of prescribing trends of 
antipsychotic medications in youth, especially for behavior control.  The second manuscript 
presents a literature review pertaining to adolescent risk behaviors that may contribute to 
depression based upon the Centers for Disease Control’s (2013) screening recommendations.  
Based in part upon the literature from these first two manuscripts, a descriptive study was 
performed which examined risk behavior screening practices and the patterns of behaviors and 
risk level among patients treated at an adolescent health clinic in the southeastern United States 
using the PARS screening instrument.  Finally, the third manuscript presents results from this 
study and implications for practice improvement services for depression screening in this at-risk 
population. 
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Introduction 
 Antipsychotic medications were developed in the 1950s to treat symptoms associated 
with psychotic disorders, such as schizophrenia.  In the last few decades, these medications have 
also been approved by the Food and Drug Administration (FDA) to treat other psychiatric 
disorders in adults such as bipolar disorder, schizoaffective disorder, and as an adjunct 
medication in treatment resistant major depressive disorder (Elsevier, Gold Standard, Inc., 2013).  
The older medications, known as typical or first-generation antipsychotics (FGAs), have been 
effective in treating positive symptoms of schizophrenia such as hallucinations, delusions, 
aggression, and hostility.  Unfortunately, the therapeutic effects of these medications have been 
inadequate in the treatment of negative symptoms of schizophrenia such as apathy, social 
isolation and withdrawal, and lack of motivation.  In addition, these medications have a high rate 
of extrapyramidal side (EPS) effects that include dystonic reactions (involuntary spasm or 
jerking of muscles in the body), akasthisia (the inability to sit still due to involuntary movements, 
especially in the limbs), drug-induced Parkinsonism, and tardive dyskinesia (involuntary rolling 
of the tongue and twitching of the face, trunk, and/or limbs).   
 Atypical, or second-generation antipsychotics (SGAs) were introduced in the 1980s and 
are similar to the FGAs in reducing psychotic symptoms in patients with psychosis but with 
fewer and less severe side effects than the FGAs (Lieberman et al., 2005).  Although they have 
proven to be as effective as FGAs in treating the symptoms of psychosis, the atypical 
antipsychotics have shown to have a higher incidence of metabolic adverse effects and weight 
gain.  
  Even with this increased risk for metabolic adverse effects, there are, however, specific 
SGAs that have been approved for use in the pediatric population for certain disorders, including 
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irritability with autistic disorders, schizophrenia, and bipolar I disorder with mixed or manic 
episodes.  However, many children are also treated with SGAs for psychiatric illnesses that have 
no FDA approval; for example, Doey, Handelman, Seabrook and Steele (2007) reported that 
impulsivity, aggression, obsessive-compulsive disorder, and insomnia were frequently treated 
off-label with SGAs.   
 The purpose of this literature review is to identify trends associated with SGA use within 
the population under the age of 18, as well as prescriber practices, psychiatric conditions 
associated with SGA use, and safety issues with antipsychotic medication in the pediatric 
population, specifically in adolescence. 
Methods 
Search Methods 
 Literature from 2006 to 2013 was reviewed from searches in PubMed, CINAHL, 
MEDLINE, and PsychLit with the following search terms:  antipsychotics, adolescents, children, 
youth, English language, published in the last decade, guidelines, prescribing, trends, mental 
illness, psychosis, aggression, schizophrenia, mood, bipolar, Medicaid, insurance.  Studies were 
limited to those that had included primarily second-generation antipsychotic medication use in 
persons 18 and under without regard to any specific diagnoses, treatment setting, and without a 
focus on specific racial/ethnic group or gender.    
Search Results 
 The above databases were searched for abstracts with the key word search terms. The 
search yielded 17 articles.  Ten of these articles were chosen based upon the quality of the 
study/paper and the authoritative source and were made up of systematic literature reviews, 
practice parameters, retrospective trend analyses, and cross-sectional studies.  
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Findings 
 All of the 10 studies included in this literature review examined the potential for intrinsic 
safety issues associated with the use of antipsychotic medications in young people.  Two studies 
reviewed the prescribing trends in privately insured children, three studies primarily reviewed 
trends in publicly insured children and the possible explanations for this development, two were 
primarily to generate practice parameters, two specifically studied the adverse effects of these 
medications in young people (although all studies noted this information but in much less detail) 
and one study reviewed much of this information from the other studies and included more 
recent data of use across 11 health maintenance organizations.  As the availability of inpatient 
treatment for psychiatric illnesses have substantially decreased, almost all of the studies 
reviewed were based in a physician office setting:  primary care, family practice, or psychiatry.  
 The patterns of antipsychotic medication prescribing and use are of great importance to 
professionals who treat the pediatric population; the consequences of not following the best 
practice guidelines fall mainly on the child, no matter what physician specialty is prescribing the 
medication.  Rettew et al. (2015) found evidence that antipsychotic medications were not 
necessarily being handed out to treat insignificant behavioral problems, as has been postulated in 
some of the research, but they found several areas where providers were not following best 
practice recommendations.  One particular discovery they found was that antipsychotic 
medications were being prescribed following the guidelines only about half of the time and only 
followed FDA-approved conditions about one-fourth of the time.    
Insurance influence on prescribing trends 
 The frequency of psychotropic medication prescribing has increased in the last 2 decades, 
particularly with antipsychotic medications.  According to Zito, Burcu, Ibe, Safer, and Magder 
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(2013), antipsychotic use in youth within the Medicaid population has dramatically risen in 
conjunction with the overall increase found in adolescents.  Many reasons have been 
hypothesized for the increase in rates, especially in the public insurance sector.  For example, 
higher poverty rates among those insured by Medicaid have been associated with reduced access 
to comprehensive services; this has led the demand for more rapid symptom stabilization for 
behavioral problems in children.  In addition, a greater frequency of psychiatric conditions and 
behavior disorders are diagnosed in children who are insured by Medicaid, decreased provider 
reimbursement for thorough and time consuming mental health assessments, and pressure from 
stressed families may make antipsychotic medications a more attractive option for treatment 
(Zito, Burcu, Ibe, Safer, & Magder, 2013; Pathak, West, Martin, Helm, & Henderson, 2010; 
Harrison, Cluxton-Keller, & Gross, 2012).   
 Changes in prescribing patterns can be attributed in part to:  scientific advances in 
antipsychotic medications from FGAs to SGAs (each with a different side effect profile); FDA 
approval for certain SGAs in the diagnosis of bipolar disorder, schizophrenia, and autism 
spectrum disorder in young people; an increase in the Hispanic population; and increased 
coverage for the children’s insurance program in each of the state’s Children’s Health Insurance 
Program  (SCHIP).  For example, Zito et al. (2013) identified the predominant clinical and 
demographic characteristics of youth who had the highest rates of antipsychotic use.  These 
included the youth who were more family income level eligible (qualified for state and federal 
assistance like SCHIP) over youth who were considered vulnerable (who were in the foster care 
system or received Supplemental Security Income [SSI] for a disability). In addition, very young 
children (ages 2 to 4 years, even though no FDA approved disorders for the use of SGAs exist 
for this age group) showed an increase in use similar to youth ages 10 to 17, and the greatest 
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proportionate youth increases were in the Hispanic population. Externalizing behavior disorders 
were more frequently treated with antipsychotic medications compared to diagnoses of 
schizophrenia, psychosis, or other severe conditions of development.   
 The use of antipsychotics for treatment of behavioral issues greatly exceeded that of 
treatment for psychotic disorders.  Pathak, West, Martin, Helm, and Henderson (2010) came to 
similar conclusions in their study.  In looking at the Arkansas Medicaid program during the years 
2001-2005, they found that the number of children treated for the first time with SGAs increased 
from 1,482 to 3,110 during the duration under study.  Overall, almost half of the youth who 
received a SGA in these studies had no supporting diagnosis to justify the use of these 
medications; over half of this number of antipsychotic use was for attention-deficit hyperactivity 
disorder (ADHD)—a condition that has not been approved by the FDA for treatment with 
antipsychotic medications (U.S. Department of Health and Human Services, Agency for 
Healthcare Research and Quality [AHRQ], 2013).  Interestingly, the majority of providers who 
prescribe antipsychotic medications to pediatric patients for non-FDA approved off-label use in 
the outpatient setting are psychiatrists (64.1%) followed by pediatricians (9.5%), nurse 
practitioners (7.7%), unspecified (6.3%), general practice/family medicine (4.9%), and all others 
(7.4%) (Chai, Mehta, Moeny, & Governale, 2013).  
 In office-based settings, Olfson, Blanco, Liu, Moreno, and Gonzalo in 2006 found that 
antipsychotic medications were prescribed more often for young people on Medicaid more so 
over young people covered under private insurance, possibly due to the effect of higher mental 
health disabilities and foster children being insured through Medicaid (Fortuna, Fulwiler, Stone, 
Smith, & Biebel, 2008).  But a later study by Olfson, Blanco, Liu, Wang, and Correll (2012) 
noted continued increases of antipsychotic use in youth across the board, regardless of the pay 
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source (although publicly insured youth continued to have the most antipsychotic medication 
management visits); males diagnosed with a disruptive behavior disorder had a majority of these 
visits.  Notably, for the years 2005-2009, the authors found the bulk of the antipsychotic 
medications prescribed were for a disruptive behavior disorder diagnosis; the FDA has not 
approved treatment for these disorders with an antipsychotic medication.  Likewise, they found 
that a diagnosis of bipolar disorder in youth was a common reason for prescribing these 
medications, even more so than for adults, yet diagnosing bipolar disorder in youth is not an 
accurate science.   
 These trends are not relegated solely to the publicly insured youth.  In a study of privately 
insured, very young children (ages 2 through 5) during the years 1999-2001 and 2007, Olfson, 
Crystal, Huang, and Gerhard (2010) noted that the overall amount of psychotropic medications 
prescribed to this age group did not differ much in the two time periods under study, but the 
types of psychotropic medications filled differed significantly with the greatest increase in 
antipsychotic medications.  Males were more commonly treated with antipsychotic medications, 
and the most common diagnosis for antipsychotic use was bipolar disorder (as was discovered by 
the authors again at a later date).  Olfson et al.’s (2010) final assessment concluded that the 
majority of these very young privately insured children who were treated with an antipsychotic 
medication did not receive the most rudimentary mental health services during this time period 
such as a thorough mental health assessment, any type of psychotherapy, or a consult with a 
psychiatrist.  This may be due to lack of treatment access.  Repeatedly, these studies noted that 
aggressive behaviors seem to be the end point that antipsychotic medications are being targeted 
for in off-label use among patients under 18 years of age.  
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Conditions treated with antipsychotics 
 Olfson et al. (2012) noted that a possible explanation for the increase in antipsychotic 
prescribing in younger people was the FDA approval for certain medications to treat the 
following conditions in youth:  bipolar disorder, schizophrenia, and irritability associated with an 
autistic spectrum disorder as well as certain published clinical trials and practice guidelines for 
use in unapproved conditions.  Researchers examining the use of antipsychotics in children with 
these approved diagnoses found that improvements in the symptoms of irritability, self-injurious 
behavior, aggression, and tantrums associated with Autism Spectrum Disorder (ASD) are 
significant, especially with the SGA risperidone (Aman et al., 2008; Pandina, Bossie, Youssef, 
Zhu, & Dunbar, 2007; Harrison, Cluxton-Keller, & Gross, 2011).  In addition, Risperidone is 
approved treatment for schizophrenia and bipolar disorders in adolescents; aripiprazole was later 
approved for treatment of schizophrenia and bipolar I disorder in children ages 10-17 (Pathak et 
al., 2008; Crowley et al., 2014).    
 Bipolar disorder and autism spectrum disorder diagnoses have increased markedly in 
youth over the past decade, and along with the lower EPS risks with SGAs over FGAs, FDA 
approval for use with certain conditions, and the overall level of increased prescriber comfort 
with these medications probably account for some of the increases in antipsychotic use.  Pathak 
et al. (2008) also brought up other plausible reasons for the upsurge:  the rise in behavioral 
managed care alongside strictly limited reimbursement for psychotherapy leading toward a 
greater use of pharmacological interventions; mental health treatment stigma may be to a lesser 
degree; and a greater acceptance of psychotropic medications in the general population as 
pharmaceutical manufacturers use intense marketing to consumers.  Harrison, Cluxton-Keller, 
and Gross (2011) and James (2010) proposed similar possible reasons for the increased 
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antipsychotic use in children, especially for off-label treatment. These include the acceptance of 
psychotropic medication use in the pediatric population, limited access and inadequate supply of 
mental health professionals to treat this population, demand for rapid treatment that is affordable 
(unlike therapy which can take multiple visits and cost more than what a family can afford), 
limited provider time and reimbursement issues for treating behavioral problems (without 
medications), and the options for treatment in vulnerable populations that have limited resources 
and access to care.   
 The American Academy of Child and Adolescent Psychiatry (AACAP, 2011) found that 
antipsychotic prescribing has dramatically increased in the last 17 years, especially for mood 
disorders and by non-psychiatrist physicians, and they noted off –label use for antipsychotics 
(particularly SGAs) have been a major influence on the prescribing of these medications to 
youth, even without FDA approval.  Currently, the FDA approved conditions for antipsychotic 
use in minors are schizophrenia, bipolar I disorder (manic or mixed), and irritability found with 
autism; the medications approved for these conditions are:  aripiprazole, olanzapine, 
paliperidone, quetiapine, and risperidone (FDA, 2013).  Of these, risperidone and aripiprazole 
are the only medications approved for use in ASD in youth ages 5-11.  The Centers for Medicare 
and Medicaid Services (CMS) report, “More than three-fourths of youths on Medicaid are taking 
one of these [atypical antipsychotics] medications for an indication that is not FDA approved” 
(U.S. Department of Health and Human Services, AHRQ, CMS, pg. 2, 2013).  Supporting the 
CMS report, Pathak et al. found in their study, 41.3% of new users of antipsychotic medications 
(SGAs) under the age of 18 were for a diagnosis not approved by the FDA; Penfold et al. (2013) 
also discovered that the majority of children on antipsychotic medications did not have one of 
the approved conditions for use.  Interestingly, in the European Union countries aripiprazole is 
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the only approved antipsychotic medication for youth ages 15-17 who have schizophrenia, 
although a few countries also have the approval for use of risperidone for severe disruptive 
disorders in children and adolescents (Findling et al., 2008).  The use of these medications is not 
without great risks to the child such as weight gain, cardiometabolic effects, and the unknown 
long-term effects of use on a child’s growth and brain development. 
Safety 
 Antipsychotic medications, especially the newer SGAs, have unfortunately contributed to 
the pervasiveness of obesity in the medicated schizophrenic population; current estimates range 
from 40 to 60% versus 30% of the general adult population (Sokal et al., 2004).  In addition, use 
of the SGAs increases the risk of acquiring or exacerbating type II diabetes, especially in female 
youth (Nielsen et al., 2014; Cohen, Bonnot, Bodeau, et al., 2012).  SGAs can cause a substantial 
amount of weight gain as well as an increased risk for metabolic changes; each medication has 
varied levels of these effects.  Aripiprazole has a higher percentage of EPS related effects in 
youth over adults and is not indicated as a monotherapy treatment for major depressive disorder 
(Nielsen et al., 2014).  In addition, treatment with aripiprazole is associated with increased 
suicidal ideation among people under the age of 24 (U.S. Department of Health and Human 
Services, AHRQ, CMS, 2013).   Many adverse effects have been observed with the use of SGAs 
among the child and adolescent population including weight gain and hyperlipidemia in 
adolescents taking olanzapine, increased metabolic effects with paliperidone, blood pressure 
increases associated with quetiapine, and weight gain with risperidone (Panagiotopoulos, 
Ronsley, Elbe, Davidson, & Smith, 2010; Correll, & Kratochvil, 2011; Cohen, Bonnot, & 
Bodeau, 2012).   
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 De Hert, Dobbelaer, Sheridan, Cohen, and Correll (2011) conducted a systematic review 
of randomized controlled trials (RCT) with SGAs to investigate the adverse metabolic effects of 
these medications in the under age 18 population.  They reviewed 31 RCTs that included 3,595 
patients in the pediatric population.  This review indicated that youth under age 18 had a much 
greater risk of hyperprolactinemia, weight gain, and other metabolic disturbances resulting from 
treatment with SGAs.  In their study, ziprasidone had the lowest risk for weight gain; 
aripiprazole, quetiapine and risperidone showed moderate amounts of weight gain; and 
olanzapine showed the most weight gain effects.  This weight gain also tended to be in younger 
patients with ASD who had no prior experience with SGA treatment.  Seida et al. (2011) 
conducted an extensive systematic literature review to investigate safety and efficacy of FGAs 
and SGAs in youth under 24 years of age.  They too found that olanzapine caused more 
dyslipidemia and weight gain, but fewer prolactin-related events than risperidone; olanzapine 
caused more weight gain than quetiapine.   
 Children may suffer different and/or more serious side effects than adults from taking 
antipsychotic medications.  Different rates of absorption and distribution within the tissues and 
cells exist due to the relative mass of the liver and kidneys (when adjusted for weight), and 
children’s bodies have more water and less fat compared to adults. This could potentially be a 
contributing factor for higher risk of metabolic adverse effects among youth treated with SGAs 
compared to those experienced by adults.   It is imperative that safe-dose range limits are 
established and disseminated in practice guidelines.  This prompts and supports the need for 
baseline measures recorded for every child who is prescribed antipsychotic medications and 
continued monitoring for the duration of treatment.  
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Discussion 
 The objective of this literature review was to identify trends in the use of antipsychotic 
medications in children and adolescents.  Based upon the literature critically appraised for this 
paper, findings indicate an increasing trend in the prescribing of antipsychotic medications in 
young people (specifically SGAs) by many providers, some not specialized in psychiatry or 
mental health.  This clinical problem is heightened when considering that the FDA has not 
approved the use of these medications for several of these illnesses.  Disruptive, aggressive, 
oppositional, and other behaviors that do not respond to parental controls appear to be a common 
reason for providers choosing this route of treatment.  A small number of SGAs are approved to 
treat some psychiatric conditions in young children and adolescents, but most of the children on 
the medications in the reviewed studies did not have one of the approved diagnoses.  The main 
concern for using these medications in young people is their increased risk of experiencing 
adverse side effects such as weight gain and/or metabolic changes; these could have devastating 
consequences for health into adulthood.  A major concern is that these are just the adverse effects 
that have been studied—no long-term data exists for the effect these medications could have on 
growth and brain development.  
Implications 
 Important concerns that need to be addressed in future research include strategies to 
improve access to psychosocial treatments with qualified providers, the urgent need for high 
quality studies to determine the efficacy and safety of off label use of antipsychotic medications, 
and standardization for outcome measurements for the purpose of ascertaining clinically 
important outcomes and the degree to which changes in symptoms and functioning are 
significant.  Telemedicine psychiatry may be a viable option to improve accessibility in areas 
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where pediatric psychiatrists or collaborative physicians are limited.  Additional studies are 
needed to examine the dose-related effects of the different medications on weight gain, metabolic 
adverse effects (dyslipidemia, glucose, prolactin, blood pressure, liver function) in addition to 
health-related quality of life, social functioning, and the effects on the involvement in the legal 
system (Harrison, Cluxton-Keller, & Gross, 2012; Seida, et al., 2012; De Hert, et al., 2011).  A 
2012 AHRQ study of FGAs and SGAs in children and adolescents concluded that further 
research was needed the most in three categories including long-term outcomes for effectiveness, 
long-term risks of medication use, and differences in efficacy, effectiveness, or incidence of 
adverse effects in the various subpopulations of young people who take antipsychotic 
medications.   
Further Implications 
 In addition to the need for increased standardization of off-label use of antipsychotic 
medications and increasing access to other psychotherapeutic modalities of treatment, other 
therapeutic parameters must be investigated.  Some of the areas of treatment that need further 
study include determining the numbers of very young children unnecessarily diagnosed with 
psychiatric disorders, such as bipolar, and needlessly prescribed antipsychotic medications and 
safety issues among children prescribed several psychotropic medications simultaneously.  
Comprehensive psychiatric assessment must be performed before starting any psychotropic 
medication in a young person in order to arrive at a precise decision for the best treatment. 
 For the child’s safety, non-pharmacological interventions should always be utilized as a 
first line of treatment including such interventions as parental skills training and support when 
indicated.  Many behavioral problems in children are often strongly associated with problematic 
family relationships and stressful home environments; medications cannot fix these core 
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problems.  Adequate provider training for use of these medications should also be a priority.  As 
a best practice, primary care providers should collaborate with psychiatrists or psychiatric nurse 
practitioners before prescribing psychotropic medications.  However, the collaboration between 
primary care and mental health professionals rarely occurs (Wissow et al., 2013).  To address 
this treatment barrier, some states have created monitoring oversight for collaboration between 
pediatricians, primary care providers, and specialists in child psychiatry (Medicaid Medical 
Directors Learning Network & Rutgers Center for Education and Research on Mental Health 
Therapeutics, 2010).  Some states have started implementing strict monitoring for the use of 
psychotropic medications in children, especially antipsychotics, in the Medicaid population 
(Colorado Department of Health Care Policy and Financing, Colorado Department of Human 
Services, 2013).  These programs are a step forward in ensuring the safety of our children.   
Conclusion 
 The trend in the use of antipsychotic medication in young people has increased 
dramatically over the last 15 years, many prescribing practices without the benefit of psychiatric 
specialty collaboration or for FDA-approved conditions.  The publicly insured youth have the 
highest use of these medications but increases in privately insured have also been noted.  
Antipsychotic medication can have serious adverse effects on youth; more so than on adults, and 
this outcome can be found in most of the literature published regarding antipsychotic use among 
children.  However, these studies are limited, and the long-term effects on children have not been 
fully examined.  
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Abstract 
Title:  Evaluating risk-behavior screening for identifying adolescent depression: a literature 
review 
Aim: The purpose of this literature review is to analyze and present recommendations regarding 
the identification of adolescent depression from the 2013 Centers for Disease Control 
recommended behavior domains on risk screening instruments.  
Background:  Over 2 million youth report a major depressive episode yet 60% of these youth 
did not receive any kind of treatment.  Depression is consistently the highest risk factor for 
adolescent suicide.  Depression screening has been recommended for primary care and risk-
behavior instruments are commonly used.  Domains other than the “mental health” domains on 
these instruments may indicate depression as well and need to be taken into consideration when 
assessing for adolescent depression in primary care. 
Design:  Integrative literature review 
Method:  MEDLINE, The Cochrane Library, PubMed, PsychINFO, and CINAHL databases 
were searched for studies from search terms:  adolescents, high-risk behavior, youth, screening, 
depression, correlates, primary care, smoking, substance use, predictors and depression, 
domains, assessment, behavior and emotional disorders, mental health, teenagers.  The literature 
on this topic is limited.  Most of the 8 studies narrowed down for inclusion in this review were of 
a cross-sectional design. 
Results:  Identified factors potentially associated with adolescent depression include cigarette 
smoking, the environment surrounding school/academics, stress associated with worries about 
the family stability, gender differences on prevalence of depression, and attitude/perceptions 
from a negative cognition.  
Implications:  Although few high quality studies were available, the identified factors noted are 
included in the domains of risk-behavior screening instruments.  These should be taken into 
consideration as possible indicators for the presence of depression when triggered and the youth 
should be assessed for need of further evaluation.  
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 Depressive symptoms were reported by 2.2 million youth ages 12-17 in the United States 
in 2012; sixty percent did not receive any kind of treatment (Substance Abuse Mental Health 
Services Administration [SAMHSA], 2012).  Depression is consistently the most common risk 
factor for adolescent suicide, which has been the 3rd leading cause of death for teens for many 
years (Gould, Shaffer, & Greenberg, 2003; the Centers for Disease Control [CDC], 2012).  In 
2009 the US Preventive Services Task Force (USPSTF) recommended screening for adolescent 
depression in primary care, but levels of depression screening in primary care have been 
suboptimal (Irwin, Adams, Park, & Newacheck, 2009).  
 Risk behavior assessment tools have also been recommended to screen for depression in 
adolescents in primary care (CDC, 2013; The National Institute of Health Care Management 
[NIHCM], 2010).  Several screening tools are available for clinicians in the assessment of risk 
factors associated with depression in youth.  For example, Salerno and Barnhart (2014) evaluated 
the 21-item Rapid Assessment for Adolescent Preventive Services (RAAPS) for utility in 
identifying adolescent depression in primary care services compared with the Patient Health 
Questionnaire-Adolescent (PHQ-9), considered the “gold standard” for depression screening in 
primary care; the RAAPS was shown to be a valid and reliable measure of adolescent depression 
and has been recommended by the USPSTF (2009).  However, the currently available tools have 
shown wide variations in the inclusion of relevant assessment domains that could alert the 
clinician to the need for further evaluation and referral for depression, and provider interpretation 
on the need for further evaluation can vary depending on the screening tool used in the 
assessment.  The purpose of this literature review is to analyze, identify, and propose alternative 
behavior characteristics to assess for adolescent depression from the CDC (2013) recommended 
behavior domains on risk screening instruments.  
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Background 
 The goal for adolescent depression screening is to increase rates of identification of 
depression and implement early interventions such as referral, more in-depth screening, 
treatment, and follow-up.  Ultimately, earlier interventions may decrease the risk of negative life 
outcomes that can take place when depression is not identified and treated (USPSTF, 2009).  
Depression screening has been shown to be effective at identifying depression in adolescents 
leading the USPSTF to make several screening recommendations in 2009.  However, these tools 
are specific to depression and as such, are infrequently offered to adolescent patients in the 
primary care setting because providers report time and training as barriers in their screening 
practices (Irwin et al., 2009; Olson et al., 2001).   
 Risk behavior screening may be a more practical approach and can yield much 
information about the overall health of an adolescent.  The CDC (2013) has identified several 
risk behaviors for morbidity and mortality in adolescents and recommended evidence-based risk 
screening for these behaviors, or domains, in the primary care setting.  These risk behaviors 
include unintentional injuries; presence of violence/aggression; mental health issues; tobacco 
use; use of alcohol and other drugs; sexual behaviors contributing to unintended pregnancy, 
sexually transmitted infections (STIs) and HIV; unhealthy dietary behaviors and lack of physical 
activity.  A number of protective factors have also been identified such as social support, life 
goals, and/or a trusting relationship with an adult (Michigan Quality Improvement Consortium 
[MQIC], 2013).  Engagement in risky behaviors can greatly affect the present and future mental 
health of an adolescent, and these behaviors are evident in adolescents with depressive symptoms 
much more than those without depressive symptoms thus raising their risk for further mental 
illness (Institute of Medicine [IOM] and National Research Council Committee on the Science of 
 
 27 
Adolescence, 2011; Waller et al., 2006).  Since 2013, the MQIC, along with the Agency for 
Healthcare Research and Quality (AHRQ), have recommended that adolescent risk behavior 
screening should be performed at least annually with a validated screening tool.  There is a lack 
of systematic evidence-based guidelines for the identification of potential depression as 
determined via a risk assessment-screening instrument.  However, evidence-based studies have 
identified risk behaviors associated with an increased risk for depression (IOM and National 
Research Council Committee on the Science of Adolescence, 2011; Forman & Davies, 2003; 
Haarasilta, Marttunen, Kaprio, & Aro, 2004; Richmond, Mermelstein, & Metzer, 2012), but 
limited data exist to connect those known risk factors with their correlated domains on a risk 
screening instrument.    
Methods 
Search Methods 
 The MEDLINE, Cochrane Library, PubMed, PsychINFO, and CINAHL databases were 
searched for studies using the following search terms:  adolescents, youth, high-risk behavior, 
screening, depression, correlates, primary care, smoking, substance use, predictors and 
depression, domains, assessment, behavior and emotional disorders, and mental health.  Most 
studies were of a cross-sectional design as the literature was limited. 
 Inclusion criteria for the studies in this review were:  (a.) males, females, or mixed gender 
between the ages of 12-21 years; (b.) all races and ethnicities; studies written in the English 
language; (c.) settings to include primary care, pediatrician offices, schools, or outpatient 
settings; (d.) the use of screening/assessment tools for their study with measures to include 
depression/depressive symptoms along with other areas of behavior and/or emotion; (e.) outcome 
of study is associated with depression (connection or note to other domain areas); and (f.) studies 
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within the last decade.  Included studies did not require a formal diagnosis of depression among 
the participants, but they did need to identify the presence of depressive symptoms.  Exclusion 
criteria included (a.) a focus on participants who dropped out of school, (b.) juveniles in the 
justice system, (c.) incarcerated youth, (d.) adolescents in substance abuse treatment, and (e.) 
institutionalized youth.  Studies that included only college attendees, focused on a specific 
racial/ethnic group, or concerned primarily with adult outcomes were also excluded. 
Search Results 
 The databases were searched for abstracts meeting the key word search terms.  Initially, 
38 studies met the inclusion criteria of which 22 were eliminated with the exclusion criteria.  
Sixteen studies remained.  No randomized controlled trial (RCT) studies met the inclusion 
criteria for this literature review. 
Findings 
 Of the 16 studies included in this literature review several evaluated early identification 
of potential depression in adolescence in primary care and adolescent risk screenings/tools 
(Salerno and Barnhart, 2014; NIHCM, 2010; American College of Preventive Medicine 
[ACPM], 2011).  Three studies reviewed the relevance of the school environment on behaviors 
contributing to adolescent depression (Haarasilta et al., 2004; Richmond, Mermelstein, & 
Metzger, 2012; Respress, Morris, Lewin, & Francis, 2013), two studies examined the 
interpersonal relationship factors (Yaroslavsky, Pettit, Lewinsohm, Seeley, & Roberts, 2013; 
Dumont & Olson, 2012), three studies considered the characteristics of the individual in relation 
to depression (Dumont & Olson, 2012; Rood, Roelofs, Bogels, & Meesters, 2012; Rockhill, et 
al., 2013), and several looked at gender as a potential mediating factor and the specific behaviors 
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related to gender (Seeley, Stice, & Rohde, 2009; Waller et al., 2006; Rubin, Gold, & Primack, 
2009). 
 Several themes emerged from this review, and some aspects of one theme may converge 
with another theme.  The predominant themes included specific environmental influences 
potentially influencing the development of depression, interpersonal relationships and individual 
characteristics and vulnerability for depression; the role of gender and gender specific behaviors 
also emerged as a theme suggesting increased risk for depression.  Most of the studies mentioned 
differences in presenting complaints and/or symptoms between adolescents and adults.  The 
themes are of great importance in linking various risk behaviors to potential adolescent 
depression especially for the behaviors unknowingly connected to depression.   
Influence of peers/school environment  
 Healthcare providers have a widespread knowledge base on the risk factors for 
depression in adolescents, mainly due to treatment guidelines developed by various expert 
organizations (IOM and National Research Council Committee on the Science of Adolescence, 
2011; NIHCM, 2010; USPSTF, 2009; ACPM, 2011).  The evidence base indicates that a history 
of depression, mental or medical comorbidity, substance use, history of trauma, and many other 
factors increase the risk of developing mental health issues (IOM and National Research Council 
Committee on the Science of Adolescence, 2011).  Other more subtle factors may also influence 
the development or presence of depression.  For example, peers and friends at school are 
extremely important to an adolescent for a multitude of reasons.  Adolescence is a vulnerable 
time period in a child’s social development, and peer rejection may lead to gravitation towards 
deviant peers to decrease a sense of isolation.  The choice of peers can have a "domino effect" 
for behaviors that are associated with depression such as drug use, delinquency, and other high-
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risk behaviors (Haarasilta et al., 2004; Richmond, Mermelstein, & Metzger, 2012; Respress et 
al., 2013).   
 The influence of negative peer interactions greatly increases an adolescent’s risk for 
depression over time.  Richmond, Mermelstein, and Metzer (2012) conducted a 24-month 
longitudinal study to examine the risk and protective factors associated with deviant and non-
deviant peers in high school students.  Deviant behaviors are defined as behaviors being outside 
of the accepted cultural norm for a group or society such as drug use, promiscuity, and 
delinquency for example [Merriam-Webster, 2015].  Richmond and colleagues found that 
protective factors of non-deviant friendships decreased the risks associated with the influence of 
deviant peers with regards to cigarette smoking and alcohol use, but had no reduction effect on 
depressive symptoms.  The findings suggest a negative impact associated with peers, specifically 
on depressive symptoms.  Negative peer interactions are noted to be the most consistent factor in 
ongoing depression symptoms in adolescents and are generally related to the influences on 
behaviors that peers exert, especially with alcohol and substance use in both genders (Huang et 
al., 2014; Herres, & Kobak, 2014; Pesola et al., 2015).  As noted above, alcohol and substance 
use is linked with an increased risk for depression in adolescents. 
 The actual school environment (or lack thereof) seems to have a strong influence on the 
potential risk for depression as the stress of academic and social pressure is increased.  
Haarasilta, Marttunen, Kaprio, and Aro (2004) found that adolescents, especially between the 
ages of 15-17, were more apt to experience a major depressive episode if they smoked cigarettes, 
had chronic medical conditions, and/or did not work or attend school at the time of the study.  
The school environment and poor school functioning has been associated with depression in the 
influential factors of academic performance, the perception of prejudice/discrimination by peers 
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and/or teachers, and socioeconomic status (Respress et al., 2013; Seeley, Stice, & Rohde, 2009).  
Interestingly, the perception of peer prejudice and teacher discrimination was significantly 
related to depressive symptoms with the teacher as a much stronger influence than the peers 
(although this finding was mostly in whites and minorities and not with blacks); parental 
education and neighborhood poverty had a more powerful influence with black adolescents.   
 School performance has also been linked to depressive symptoms; Respress et al. (2013) 
found that low GPA (grade point average) scores were strongly associated with depressive 
symptoms for all racial groups.  Perception of discrimination in the school setting was an 
additional predictor for depression in this study.  Wanner, Morin, and Vitaro (2005) found that 
the risk for a depression trajectory was much higher for girls with a greater level of a reactionary 
temperament who were rejected by their same sex peers.  This contrasts the earlier theme of 
negative peer influence even though the outcome is similar; rejection is more of a behavior 
dictated by others while a negative peer influence involves behaviors that are controlled by the 
individual based upon the peer influence (although this vulnerability may stem from peer 
rejection initially).  The school environment can have a robust impact on a youth’s health both 
positively and negatively.  Negatively, this may occur when a teen feels discriminated against by 
classmates and teachers; teachers are supposed to be accepting of all kids and have a huge 
influence on academic performance.  Thus, a perceived relational instability can lead to 
associating with peers who may also feel shunned and who display acting out/risky behaviors, 
potentially leading the teen to start smoking and drinking.  If the teen has the ability to make 
friends who are not of the risk-taking circles those friends may be able to help offset the 
influence of the shunned group. 
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Family factors 
  The effects of a dysfunctional school environment and/or peer influences are not the only 
possible predictors for the onset or course history of depressive symptomology in adolescents.    
It is well known that adolescents who experience parental conflict are at a greater risk for 
depression (Connell & Dishion, 2008).  Parental influence on adolescent depression is not 
relegated solely to conflict, however.  Ideally, the family serves as a source of stability during a 
tumultuous time in the life of a young person, and if a teen does not perceive that the family as 
whole functions on a stable and secure level then the teen has a difficult time obtaining the 
emotional permanence needed for self-efficacy.  Lack of parental support and stability can shake 
the foundation of an adolescent’s identity of self with a negative impact on overall social 
functioning through the lifespan.  This insecurity and instability appear to have a profound 
influence on a youth's emotional well-being.  Dumont and Olson (2012) studied somatic and 
emotional predictors for depression in primary care and found significant associations with 
stress, anger, and worries about family substance use on positive depression screens.  An 
adolescent’s perception of family security regarding the future and the ability to give support 
could influence the increase or decrease in depressive symptoms, especially in the area of 
financial concerns; this factor especially affects adolescent females (Forman, & Davies, 2003; 
IOM, 2011; Seeley, Stice, & Rohde, 2009).  
Gender  
 The mechanism by which risk behaviors affect girls seems to be different than in boys, 
resulting in a wide variety of outcomes between the two genders.  This divide includes the 
majority of risky behaviors in which this population engages:  BMI and body image, substance 
use, sexual activity, relationships, and smoking.  When boys and girls were compared with the 
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same risk behaviors of moderate substance use and sexual activity, girls consistently had more 
depressive symptoms than boys; the recommendation was made that girls who engage in high- 
risk behaviors, even at the experimental level, should be screened for depression (Waller, et al., 
2006).  This seems to be specifically the case for sexual activity.  The association between sexual 
activity, sexual risk behavior, and depression symptomology in females is especially strong.  Of 
the reviewed studies that addressed sexual activity and sexual risk behavior in adolescence, all 
noted that higher levels of depressive symptoms were found in females that engaged in greater 
sexual risk behavior activity, but it was unknown if prior histories of depression could have 
potentially contributed to this behavior or not (Rubin, Gold, & Primack, 2009; Seeley, Stice, & 
Rohde, 2009; Khan et al., 2009; ACPM, 2011; Waller et al., 2006).  For example, Waller et al. 
(2006) found that every risk behavior among females increased the risk for depression symptoms 
in adolescence.   
 The need for emotional permanence and security seems especially relevant since young 
women appear to be more strongly influenced by rejection and perceived instability in their 
relationships (Grant et al., 2006; Seeley, Stice, & Rohde, 2009).  This perception would logically 
increase the risk for an adolescent trajectory for depression into adulthood (Yaroslavsky et al., 
2013).  Although negative perceptions in the area of interpersonal relationships affected both 
genders, they found that girls were affected differently, which supports the ACPM's (2011) 
recommended guideline for adolescent depression.  Having a tendency to ruminate on negative 
inferences from a traumatic event, or just making negative inferences in general, was positively 
related to depressive symptoms in adolescent girls, especially in the areas of achievement and 
appearance (Rood et al., 2012; ACPM, 2011).   
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Internal Factors 
 Depression in youth has unique characteristics:  specific negative thoughts that are 
generally self-defeating, and a lack of positive thoughts.  The social information-processing 
(SIP) model helps providers to understand how depression and anxiety relate to negative 
cognitions, particularly those cognitions that relate to negative outcome expectations or negative 
appraisals of behaviors and situations.  The SIP model also helps illustrate the tendency of 
depressed youth to “sitting in the problem” instead of finding solutions to solve it (Luebbe, Bell, 
Allwood, Swenson, & Early, 2010).  This “sitting in the problem” is not necessarily rumination 
but more of an inertia that can be related to the fear of failing, comfort with being in a victim 
mentality, distrust of self and others, or an overall fear of a negative outcome.  This negative 
perception of self and the world can lead to feelings of isolation, either self-imposed or 
otherwise, which can lead to deviant peer influences (discussed in the first theme).  
Understanding this model in relation to adolescents is important to identify the potential “red 
flags” when assessing for the presence of any psychiatric condition.  
 A sense of powerlessness, feeling like a failure, insecurity, and feelings of helplessness 
nurture a negative outlook and perception of a teen’s life, leading to a pessimistic sense of self 
both internally and externally.  Taking credit for a personal success becomes very difficult as it is 
attributed to “blind luck.”  Self-reported low levels of coping, feelings of loneliness, and 
interpersonal dependency have been reported at higher percentages for those individuals who 
screen positive for depression (Yaroslavsky et al., 2013), as well as increased irritability and 
anger (Hagan, Shaw, & Duncan, 2008; Dumont, & Olson, 2012).  Luebbe, Bell, Allwood, 
Swenson, and Early (2010) noted that not only were anxiety and depression related to a more 
negative information processing style, but depression alone was related to a lower positive style 
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as well (a positive style is the ability to perceive the environment and self in a more optimistic 
view).  As noted previously, negative cognitions are positively related to depressive symptoms, 
and this phenomenon is notably reported more frequently in females.  Negative processing of 
social information and perspective is also apparent with other externalizing symptoms such as 
obesity, sedentary behavior, and unhealthy sleep hygiene (Rockhill et al., 2013; Carli et al., 
2014; ACPM, 2011).  
Discussion 
 Based upon this review of the literature the mental health domains on risk screening 
instruments, which includes depression, anxiety, self-harm, and suicidal ideation/behaviors, does 
not stand alone in alerting the clinician to the need for further depression screening in 
adolescents.  Tobacco use, alcohol/drug use, violence, adolescent stress, obesity, sexual 
promiscuity, and the lack of protective factors (such as peer influence, school connectedness, 
supportive adult relationship) are additional domains that need to be considered when evaluating 
for the presence of depressive symptoms in this population.  Although each article in this 
literature review was not of high quality, they clearly linked adolescent characteristics and/or 
behaviors with depressive symptoms.  While the same behaviors and/or characteristics were not 
studied across all of the articles, they did collectively focus on the traits that are very prominent 
in the teenage years.   
 Due to the high numbers of adolescents who suffer from depressive symptoms—without 
the benefit of any treatment—taking a few moments to thoroughly evaluate the domains on risk 
screens in a larger context may benefit many adolescents by alerting the clinician to the need for 
further assessment and/or treatment; this is the ultimate goal.  Most importantly, the results of 
risk screening behaviors must be interpreted with a more discerning eye than is currently seen in 
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practice.  This is essential when teens engage in high-risk sexual activity, particularly in females, 
who report problematic or dysfunctional family/social relationships, and/or are unable to identify 
positive qualities about self.  Family discord, problems with a boyfriend or girlfriend, or school-
related problems have been reported as a few of the more common reasons for adolescent suicide 
in the age group of 13 to 17 (Kennebeck, & Bonin, 2015).  Also, because depression is not 
identical in presentation as adults, providers need to pay close attention to the uncommon 
symptoms of depression in youth:  school problems, boredom, emotional sensitivity, frequent 
unexplained physical illness complaints, inability to concentrate, irritability, self-harming 
behaviors, and sleep disturbances (ACPM, 2011; Maurer, 2012). 
 The purpose of this literature review was to examine some of the variables associated 
with the development of depression in adolescents or its clinical course in relation to CDC 
(2013) recommended risk behavior domains on risk screening tools.  Ideally, studies included in 
this paper would all be based upon the use of consistent risk behavior screening instruments 
however; studies on factors contributing to depression in adolescents were also included.  Two 
other risk behavior-screening instruments besides the RAAPS were recommended by MQIC 
(2013):  the Adolescent Health Review (AHR,) and Bright Futures (Patient Health Questionnaire 
for Adolescents [PHQ-A], 1999) but research studies with those tools in relation to depression 
identification were not found.  In the absence of more studies from which to infer, the studies 
evaluated in this literature review primarily point out the areas that can be potential indicators in 
risk behavior screening.  The rationale for this review was the premise that depressive symptoms 
in youth may be linked to several risk factors that are not seen in adults such as family, gender, 
school environment, and internal factors, and identification of these factors could aid clinicians 
in conducting a more comprehensive assessment.  Future research should examine and evaluate 
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other risk behavior screening tools for similar outcomes with the tools recommended by 
USPSTF.    
 Unfortunately, the lack of consistency in screening instruments and methods used in the 
studies for this literature review create a limitation as well as the inability to show causality 
between the variables and outcomes.  The designs of the majority of the studies were not of high 
quality, although several showed good reliability and validity.  Lack of randomization, 
inconsistent demographics, samples, and settings hindered the generalizability of the results.  
Only one study had any longitudinal data recorded, and that was of a 24 month time period.  
Further research should be focused on the use of consistent screening instruments within similar 
settings, samples, and long-term follow-up.  Several areas of research could include an emphasis 
on gender as a mediating variable since gender was a significant factor in the outcome of several 
studies.  Other recommendations for future research should examine the differences and 
frequencies in positive results on the domains of risk behavior screening with the influence of 
race, socioeconomic status, gender, and legal guardianship of the adolescent; is there correlation 
between these factors and a positive screen for depressive symptoms?  Lastly, primary care 
providers need to consistently and diligently follow guidelines with regard to screening practices 
for their particular setting.  If only a portion of providers actually screen as suggested, the gap for 
identifying these vulnerable adolescents will remain no matter what screening instrument is used. 
Conclusion 
 In lieu of adolescent depression specific screening, risk behavior screening may be a 
more viable option in the primary care setting; it can alert the provider to an overall elevated risk 
assessment that leads to further screening.  When the depression specific domains on risk screens 
do not elicit a positive result the provider should take into consideration other domains showing 
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positive results to evaluate for the potential presence of adolescent depression.  The CDC (2013) 
recommends using risk behavior screening tools with the inclusion of domains that are the 
leading causes of adolescent morbidity and mortality:  unintentional injuries/violence; mental 
health; tobacco use; alcohol and other drugs; sexual behaviors contributing to unintended 
pregnancy, STIs and HIV; dietary behaviors; physical activity; and protective factors (MQIC & 
AHRQ, 2013).  The recommended risk screening instruments contain these domains and are a 
reliable and valid measure for adolescent risk assessments.  Guidelines regarding the 
interpretation of the screening results, as it relates to potential adolescent depression, should be 
developed so that adolescents needing further evaluation do not fall through the cracks in terms 
of receiving adequate treatment for depression. 
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Introduction 
 Researchers estimate that the prevalence of youth depression in the primary care setting 
is as high as 28% (American College of Preventive Medicine [ACPM], 2011).  Statistics in a 
2009 report from the National Research Council (NRC) and the Institute of Medicine (IOM) 
noted that the point prevalence of mental, emotional, and/or behavioral disorders among youth 
ages 12 to 17 is estimated at 14-20%, and symptoms may start to appear two to four years prior 
to the disorder being fully recognized.  The NRC also reported that mental health problems 
started by age 14 in half of all cases, with the lifetime prevalence upwards of 20%.  The National 
Strategy for Suicide Prevention (2012) stated that for students in grades 9 to 12, almost 16% 
seriously considered suicide and 7.8% of students had attempted suicide at least once in the prior 
12 months; 60% of adolescent depression sufferers reported having suicidal thoughts with 30% 
actually attempting suicide.  
 Mental illness in youth has significant consequences for the health care system, 
particularly related to financing care.  For example, the average cost of an adolescent inpatient 
care stay with a primary diagnosis of an affective disorder, particularly, was $13,397 per stay; 
total charges for 67,404 reported stays (admissions) equated to $903 million dollars for 2006 (the 
most recent data reported) (O’Connell, Boat, Warner, 2009).  In addition, adolescents with 
depression experience multiple negative outcomes that can be life-long.  The most significant 
cost of adolescent depression to society is the personal suffering from mental health problems 
due to increased morbidity that extends from psychological suffering (substance abuse, physical 
health consequences, lost occupational productivity) and decreased health-related quality of life.  
In the United States, depression and alcohol abuse are reported to be part of the top five causes 
of premature death and disability (Michaud et al., 2006).  In addition, adolescent depression has 
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a negative effect on the health and well-being of family members and significant others such as 
parental/caregiver loss of employment because of the unpredictability and stress from having a 
child suffering from mental illness, or the decreased attention and focus to the needs of other 
family members due to so much energy consumed by a sick child (Busch & Barry, 2007). 
Benefits to earlier diagnosis and treatment include reduced future medical costs; reduced 
expenditures for social and educational programs subsequent to reduced drug abuse, costs 
associated with involvement in the judicial and legal systems, and losses from student dropout 
rates.   
 Risk behavior screening can increase the likelihood of identifying youth with depression 
in a primary care setting.  The need for reliable evidence on outcomes resulting from risk 
assessments, and consequent early detection and treatment of depression is imperative to 
improve quality of life and reduce treatment costs.  The purpose of this paper is to describe 
findings from a study that investigated patterns of risk behavior screening in an adolescent health 
clinic and discuss implications of the findings for Psychiatric-Mental Health Advanced Practice 
Registered Nurses (PMH-APRN) with Doctor of Nursing Practice (DNP) degrees.  
Background 
 Since 2009, the US Preventive Services Task Force (USPSTF) has recommended 
screening for adolescent depression in primary care.  However, the proportion of depression 
screening has been below recommended rates, perhaps due to time constraints in the primary 
care setting. (USPSTF, 2009; Irwin, Adams, Park, & Newacheck, 2009).   
 In addition to the issue of time constraints, depression screening has been suboptimal for 
identification of depression in adolescents in primary care due to the use of depression screening 
tools that assess symptoms commonly seen in depressed adults, rather than behaviors linked to 
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depression specifically in the adolescent population.  Assessing for the presence of behaviors that 
are considered dangerous for an adolescent’s health and well-being is not only informative 
regarding overall health status but may reveal the potential need for further mental health 
assessment and/or treatment.  The Centers for Disease Control and Prevention (CDC, 2010) has 
identified the leading risk behaviors for morbidity and mortality in adolescents and 
recommended evidence-based risk assessments for these behaviors, or domains, in the primary 
care setting.  These include unintentional injuries/violence, mental health, tobacco use, alcohol 
and other drugs, sexual behaviors contributing to unintended pregnancy, STIs and HIV; dietary 
behaviors, physical activity.  In addition, a number of protective factors have also been identified 
as important to assess, including strong social support systems, acknowledging good qualities 
about self and having future goals, and/or a positive and trusting relationship with an adult 
(Michigan Quality Improvement Consortium [MQIC], 2013).   
 Adolescents who engage in risky behaviors are vulnerable to problems with current and 
future mental health issues such as major depression, substance use, or other psychiatric 
disorders, unintended pregnancy, poor school performance, and/or diminished social functioning.  
In addition, adolescents who experience depression have higher rates of engaging in these risk 
behaviors compared to adolescents without depression, thus increasing the risk for further mental 
illness into adulthood (Institute of Medicine [IOM] and National Research Council Committee 
on the Science of Adolescence, 2011; Waller et al., 2006).  Since 2013, the MQIC and the 
Agency for Healthcare Research and Quality (AHRQ) have recommended that risk behavior 
screening be conducted at least annually with a validated screening instrument.  Currently, a lack 
of systematic evidence-based guidelines for the use of risk assessment screening instruments for 
providers in the identification of potential depression in adolescents exists.  However, evidence-
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based studies have identified risk behaviors described by the CDC that are associated with the 
increased risk for depression (IOM, 2011; Forman & Davies, 2003; Haarasilta, Marttunen, 
Kaprio, & Aro, 2004; Richmond, Mermelstein, & Metzer, 2012).   
 Study Overview 
 The purpose of this retrospective chart review was to investigate provider patterns of risk 
behavior screening among adolescents who receive treatment at an adolescent health clinic in an 
urban setting in a south-central state of the US.  The following research questions were explored:  
1. Do providers adhere to national guideline recommendations for risk behavior screening of 
adolescents in a primary care setting?  
2. What are the patterns of provider screening for depression screening using the PARS among 
adolescents in the clinic? 
3.  What are the patterns of behaviors and risk level among adolescent patients treated at the 
clinic?  
 The study procedures were approved by the Medical Institutional Review Board at the 
sponsoring university.  Procedures to protect subject confidentiality were followed throughout 
the duration of the study.  No data/names of physicians or providers were examined, extracted, or 
recorded.  All data were de-identified prior to being recorded on the data extraction form and 
were not able to be traced back to the original medical record.  All protected health information 
reviewed was not printed or recorded. 
Methods 
 Sample.  The sampling frame consisted of 605 medical records of patients seen at the 
clinic between March 1, 2014 and March 31, 2014.  Records from this sampling frame were 
randomly selected (using Randomizer.org) and reviewed for eligibility in the study.  A total of 
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150 records were reviewed to obtain the final sample size of 84; sample size was based upon the 
number of variables examined with an over-allowance of four medical records included in the 
event of conflict or exclusion during review. 
 Inclusion and exclusion criteria.  Inclusion criteria included all adolescents, regardless 
of race, ethnicity, or gender between 12 and 18 years of age at the time of the clinic visit; 
patients seen for any reason during normal operational hours between March 1, 2014 and March 
31, 2014 were eligible for inclusion.  Exclusion criteria included adolescents with severe 
intellectual disability as documented in the medical record, non-English speaking adolescents, 
patients seen primarily in the rheumatology clinic, and patients seen as add-ons for sick visits or 
blood draws.  
 Setting.  The study was conducted in a primary adolescent health services clinic located 
in an urban area of a south-central state of the US.  Clinic staff includes social workers, 
nutritionists, psychologists, physicians, and nurses who provided a broad range of services.  
Services include specialty programs in obesity medicine and a Young Parents Program.  The 
clinic also provided treatment for chronic illness, reproductive care, nutrition counseling, 
physical exams for school, sexual abuse evaluation and treatment, substance abuse services, and 
behavioral problems counseling.  The operating hours of the clinic were from 9AM to 8PM 
Monday through Thursday and 9AM to 4PM on Friday.  An average of 750 patients were seen 
every month.  The records for the sample in this study were comprised of paper medical records.  
The clinic utilizes the Perkins Adolescent Risk Screen (PARS) for risk behavior assessments 
(Appendix A); a 17-item questionnaire, administered by the provider, that assesses for risk and 
protective factors and includes all CDC recommended risk areas.  Patients are to be screened no 
less than annually at visits to the clinic per the MQIC (2013) recommendation. 
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 Data collection.  Medical records were reviewed for 1) date of service, 2) age, 3) gender, 
4) race/ethnicity, 5) last education grade completed at time of visit, 6) who patient legally resides 
with 7) reason for visit, 8) documented PARS in chart, 9) risk level assessed for each domain on 
PARS, 10) documentation of provider referral and reasons, and 11) prior documented history of 
depression and/or anxiety.  All data were extracted from each medical record by the principle 
investigator using a demographic collection form (see Appendix B) and study variables data 
extraction form (Appendix C). 
 Analysis.   Rate of overall provider screening for risk behaviors using the PARS 
screening instrument was calculated based upon the presence of the most recent PARS in the 
chart.  Descriptive frequencies were initially calculated to assess for differences in the screening 
practices of providers based upon completeness of the PARS.  Fisher’s exact test was performed 
to measure the differences in provider screening assessment patterns by gender and race 
(screened and/or not screened).  Five risk behavior domains on the PARS were chosen to 
investigate:  Sexual Activity, Drug Use, Family Relationships and Responsibility, Friends and 
Recreation, and School.  Significance in risk behavior and risk level was computed for gender 
using Mann-Whitney U; for race and with whom the patient lives using Kruskal-Wallis Test.  
Data were analyzed using the SPSS software, version 22. 
Findings   
Patient Population   
 The mean age of the 84 adolescents was 15 (SD = 1.7).  Patient visits were made up of 61 
females (72.6%) and 23 males.  Caucasians made up 52.4% of patients, 33.3% were African 
American, 7.1% were of mixed race, and other/unknown was 7.2%.  Generally the last grade 
completed was 12th grade (25%), which coincides with the age of the patients.  The adolescents 
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generally lived in either a one-parent household (41.7%) or two-parent household (31%).  Out of 
the 84 clinic visit dates reviewed, 21 visits (25%) were due to a psychiatric-related complaint.  A 
history of mental health treatment prior to the reviewed PARS screening was present in 33.3% of 
adolescents; females accounted for 26.2% of prior psychiatric treatment and males 7.1%.  
Seventeen adolescents (20%) were referred for further assessment and/or treatment on the date of 
the PARS screening (percentage based upon 84 charts); 15 females and two males, the majority 
were referred to the dietician for high BMI or to mental health providers for depression and/or 
anxiety symptoms or for behavior problems.  The age range of those patients screened was 12 
years for the youngest and 18 years at the oldest.  The mean age for the most recent screening 
was 15 years and the mean age at data collection was 17 years (demographics, Table D1).    
Screening 
 Out of the 84 charts reviewed for this study, 7 of the charts (8.3%) did not have a 
screening instrument in the chart, did not have documentation that a screening had been 
performed, or had a completely blank screening PARS sheet in the chart.  The provider rate for 
annual screening for risk behaviors (according to the recommended guidelines) in this clinic was 
approximately 33.3% of the time; screening was performed within 1-2 years of the prior 
screening 44% of the time; and the rate for screening that was over 2 years from the prior 
screening was 22.7% of the time.  Results showed that nearly a quarter of the patients reviewed 
were not being screened within a 2-year time period, and the longest time interval between a 
PARS screening was 6 years; several charts were found to have 4 and 5 years between 
screenings.  Less the seven charts without any screen, only the domain of “Tobacco use” had a 
100% completion rate; the domain “Good qualities and future plans” was the least completed 
(left blank) at 30% (Table D2, completion percent).  There was not normal distribution for any of 
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the statistical results.  Following chi-square analysis there was no significant association between 
the variable race and the presence of a PARS screening in the chart and at least partially filled 
out (n=80; p= .67) and/or if a referral was made (n=79; p= .30), and with whom the patient lives 
with, the presence of a PARS in the chart (n=82; p= .28), and/or if a referral was made (n=81; p= 
.934); Fisher’s exact test did not find significant association between gender and presence of a 
PARS in the chart (n=84; p= .67) or if referral was made (n=83; p= .13) (Table D3).  Complete 
counts for all risk behavior domains on the PARS stratified by gender are present in Table D4. 
Characteristic of Patient Outcomes 
 Mann-Whitney U tests revealed no significant differences (p < .05) in the risk level with 
School Issues of males (n=20) and females (n=52), U=463.5, z= -.958, p= .34; Friends/Fun of 
males (n=20) and females (n=50), U=474, z= -.557, p= .577; Family of males (n=21) and 
females (51), U=493.5, z= -.832, p= .41; Drug use of males (n=22) and females (n=54), 
U=583.5, z= -.190, p= .849; and Sexual Activity of males (n=21) and females (n=49), U=439, z= 
-1.241, p= .215 (median scores across genders and variables = 1.00).  Kruskal-Wallis Test 
revealed a statistically significant difference between the variable Sexual Activity across the 
three races (Caucasian, n=37; African American, n=24; Other, n=6), chi-square (2, n=67) = 6.37, 
p = 0.41; mean rank showed that African Americans had the highest Sexual Activity risk level 
scores compared with Caucasians and Other races (medium scores across all races and variables 
= 1.00) (Table 1).    
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Table 1  
Mean Rank Between Domains and Variables of Gender and Race 
 Sex N Mean Rank Significance (p < .05) 
School Issues 
Male 20 39.33  
Female 52 35.41  
Total 72    .338 
Friends/Fun 
Male 20 34.20  
Female 50 36.02  
Total 70   .577  
Family 
Male 21 34.50  
Female 51 37.32  
Total 72    .405 
Drug Use 
Male 22 38.02  
Female 54 38.69  
Total 76    .849 
Sexual Activity 
Male 21 31.90  
Female 49 37.04  
Total 70   .215 
 
 Race N Mean Rank Significance (p < .05) 
School Issues 
Caucasian 38 33.53  
AA 24 37.00  
Other 7 36.14  
Total 69   .651 
Sexual Activity 
Caucasian 37 30.59  
AA 24 40.13  
Other 6 30.50  
Total 67   .041 
Drug Use 
Caucasian 40 37.45  
AA 26 37.65  
Other 7 32.00  
Total 73   .546 
Family 
Caucasian 37 34.93  
AA 25 35.20  
Other 7 34.64  
Total 69   .993 
Friends/Fun 
Caucasian 36 36.47  
AA 24 30.38  
Other 7 33.71  
Total 67   .158 
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 When comparison of mean scores of the five risk behaviors using a Mann-Whitney U 
Test was made between males and females, although no significant results were found, females 
were found to have higher risk scores compared with males for all the risk variables except 
within the variable “School issues,” in which males were higher.  African American females 
reported the highest proportion of risky sexual behavior levels compared with males and other 
ethnicities.     
Discussion 
 The primary finding of this review was that provider screening practices varied without 
any pattern of bias; overall completion rate was poor (Table D2).  The presence of a fully 
documented PARS in the chart was not shown to be related to, influenced or affected by gender, 
race, age, or any other demographic data that were collected.  The majority of the risk behavior 
screenings (>60%) did not take place annually, as was the recommended time frame; for several 
adolescents screening had not taken place in over 3 years.  Only one risk behavior domain 
(“Tobacco use”) was filled out with 100% completion (minus the seven charts that did not have 
any part filled out or was not in the chart).  Overall, many of the risk behavior domains on the 77 
PARS that were in the charts were left blank.  Due to so many incomplete risk behaviors 
domains, it is difficult to accurately identify relationships between variables.  It would be 
interesting to understand why providers filled out only certain risk factor domains over other 
domains.  
 In addition to wide variation in screening patterns, it was noted that African American 
(AA) females have higher rates of elevated risk levels in the area of sexual activity.  Studies have 
reported that when boys and girls were compared with the same risk behaviors of moderate 
substance use and sexual activity, girls consistently had more depressive symptoms than boys; 
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the recommendation was made that girls who act out in risk behaviors, even at the experimental 
level, should be screened for depression (Waller et al., 2006).  This seems to be specifically the 
case for sexual activity.  The association between sexual activity and sexual risk behavior and 
depression symptomology in females is especially strong.  Of the reviewed studies that addressed 
sexual activity and sexual risk behavior in adolescence, all of them noted that higher levels of 
depressive symptoms were found in females that engaged in greater levels of risky sexual 
behavior; it was unknown if prior histories of depression existed that may have contributed to 
this behavior (Rubin, Gold, & Primack, 2009; Seeley, Stice, & Rohde, 2009; Khan et al., 2009; 
ACPM, 2011; Waller et al., 2006).  Being female and African American was associated with 
elevated sexual risk behaviors and is an area of needed research for the PMH-APRN to explore 
in his/her practice and use the findings as an opportunity to better serve this population.  
 One-third of the patients in this study had a prior history of mental health problems, a 
particular variable that was not specifically studied with this review.  The PMH-APRN can and 
should be especially vigilant for depressive symptoms in these patients, as a previous history of 
mood disorder have been shown to increase the risk for developing depression later in life 
(American Foundation for Suicide Prevention, 2013).  
 Preventative visits provide the perfect opportunity for APRNs to assess the patient’s 
overall sense of well-being, including the psychosocial well-being.  Advance Practice Nurses 
(from all specialty areas) are the principle health care contacts for a large majority of patients 
with mental illness (Young, Miller, & Khan, 2010), and they need to be skillful at identifying 
depression in adolescents as well as open to “different” symptoms of depression.  This means 
utilizing a team-based approach with the PMH-APRN collaborating with other healthcare 
professionals who are involved in the patient’s care, as well as directing members of the team to 
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the most up-to-date evidence-based information pertaining to identification of mental illness in 
this patient population.  
Limitations 
 The major limitation for this review is the lack of ability to generalize study results to the 
general population of patients who were not seen at a health clinic.  The sample size was small 
considering the number of charts reviewed and that the sample was taken from a health clinic in 
a large teaching hospital.  Because this hospital is a primary resource for Medicaid patients, 
many of the charts included Medicaid.  To have a broader population included in a review, 
information would need to be gathered in different areas of the country where the sample 
population may have more varied demographic characteristics.  In addition, the rate of 
completion for provider adolescent screening utilizing the PARS was very low and the provider, 
not the patient, administered the screening tool.  This could mean that results were biased.  
Different providers prioritize risk behaviors at varying levels of importance in relation to the 
adolescent’s health and may not be based upon the priorities the adolescent feels are important 
for health and well-being.  Furthermore, providers were not interviewed to elicit information 
regarding screening practices and general thoughts on screening using the PARS for the presence 
of high-risk behaviors, especially those behaviors potentially masking depressive symptomology 
and the barriers to screening.      
Implications for Practice 
 The American Association of Colleges of Nursing [AACN] (2004) has explicated several 
core competencies for Advanced Practice Nurses who hold Doctor of Nursing Practice (DNP) 
Degrees.  These DNP competencies, or essentials, include a focus on advanced practice nursing, 
population health, clinical scholarship, interprofessional collaboration, policy, and organizational 
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and systems leadership. These competencies provide direction for PMH-NPs with DNP degrees 
to improve clinical practice and optimize outcomes for adolescents at risk for depression. First 
and foremost, screening is an integral aspect of the assessment of the adolescent in primary care, 
for the purpose of identifying and treating a major depressive disorder.  Improving the services 
provided to patients is the main goal of this Capstone.  For the potential barrier of time, 
strategies, which focus on increasing the time-effectiveness of screening, might include 
incorporating a brief screening instrument to be completed by the adolescent in the waiting area 
such as the PHQ-2.  The PARS is a 17-item questionnaire to be filled out during the health visit, 
but it can be time-consuming due to the length and amount of information it asks to obtain.  To 
this regard, the doctoral-prepared PMH-NP could contemplate making short-term follow-up 
appointments for adolescents who present with psychiatric complaints and/or a positive risk 
behavior screen on one or more domains, especially the domains that relate to adolescent 
depression and anxiety.  
 Findings are also relevant for population health. For example, strategies to promote 
awareness of depressive symptoms in this population and decrease the stigma are warranted; the 
general public needs to be aware that the depressive symptoms in a young person rarely appear 
the same as in an adult.  The DNP prepared PMH-APRN is well-suited to go into schools, both 
public and private, to promote information regarding depression symptoms and screening and 
distribute educational materials in areas students may or hold workshops. 
 Clinical scholarship can be advanced with further research related to elevated risk 
behaviors and the relationships they have on depressive symptomology and diagnosis among 
adolescent depression.  Additional domain areas need to be included or could replace other 
domains when assessing for depression and other mental health issues in order to stay current.  
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These new domains may include hours spent watching TV, playing video games, or texting; 
measuring BMI/nutrition with kind of food being consumed.  Other important health behavior 
measures include how many hours are spent alone and family history of mental health issues.  
The demographic variables of race and gender should be considered as well and possibly 
separated using different screening methods; males and females screened with different 
screening instruments.  Other areas to consider for future research would be to explore the 
relationships between adolescents who are referred due to an elevated high-risk behavior profile, 
reason for referral, and the effect of successful/unsuccessful treatment interventions.   
 PMH-NPs with DNP degrees can engage in clinical scholarship in collaborative efforts 
with other disciplines.  Outcomes research conducted in collaboration with primary care allows 
the PMH-APRN with a DNP degree can assess these screening practices and help them to evolve 
and become more accurate, less time consuming, and improve overall clinical practice services 
to this patient population. 
 This retrospective review mimics findings of other studies in manuscript 2, in that 
adolescent depression and risk behavior screening are at suboptimal levels in primary care.   
Patient-centered care is the current model for patient care and incorporating behavioral health is 
a natural integrative component and a priority to address service quality, service cost, and service 
availability.  The PMH-APRNs with a DNP degree are poised to lead this integrative 
progression.  The adolescent health clinic for this project has a fairly reliable and reciprocal 
relationship with their behavioral health colleagues (per medical record reviews for this study).  
The concern surrounds the screening process, which includes:  the provider actually using the 
screening tools per the specific clinic and completing it, minimizing provider bias and 
interpretation on the screening domains, and identifying other areas of the assessment screening 
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that may be relevant to adolescent depression.  In the primary care clinic, the DNP prepared 
PMH-APRN is ready to assist in creating policy and procedures for this clinic regarding 
adolescent depression screening.  Part of this process would include properly training the 
primary care providers in mental health skills as well as ongoing consultation to help them 
diagnose and/or manage adolescents with basic mental and behavioral health issues.  T 
 The PMH-APRN with a DNP can construct this training program that would consist of 
skills to better communicate with parents and/or teachers, use of screening measures, listening 
for the hidden “red flags” in the information given by the adolescents, and focusing on somatic 
complaints by the patient.  The program would also require annual retraining to ensure that the 
most up-to-date evidence-based interventions were being disseminated throughout the clinic.  
Outcome measures would be collected in provider fidelity with screening, provider comfort with 
mental health care in adolescent patients, follow-up tracking of depressive symptoms in the 
adolescent, family feedback, and the effect on numbers of adolescents identified with depression 
and successfully treated by the primary care provider.  The program created and implemented by 
the PMH-APRN with a DNP can be a blueprint for other clinic areas, including primary pediatric 
health and other settings of the clinic such as satellite offices.   
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Conclusion 
 As described in the first manuscript, adolescents are being prescribed antipsychotic 
medications at an alarming rate for a multitude of reasons—behavior problems being one of the 
top reasons, even among children 2-5 years of age.  It can be reasonably assumed that these 
medications may have far reaching consequences on the physical and mental health of a young 
person.  Many behavior problems that youth are being treated for with antipsychotic medications 
are also used to treat other mental health problems such as depression and anxiety.  
Unfortunately, many clinicians may be unaware that some of these behavior problems could 
have other causes and may actually stem from depression.  While limited research exists 
evaluating the risk behavior variables identified by the CDC (2012) and their influence on the 
presence or absence of depression, enough research has been completed to support a more 
exhaustive inquiry into certain risky behaviors, such as smoking or drug use, when assessing an 
adolescent.  The holistic approach to patient care that is inherent in nursing is a core component 
of Advanced Practice Nursing; this holistic base is the foundation of the exhaustive inquiry that 
is needed to accomplish a more thorough assessment of these patients.  Since 2009, the US 
Preventive Services Task Force (USPSTF) has recommended screening adolescents (age 12 to 
18 years) for depression when systems for diagnosis, treatment, and follow-up are in place.   
 The second manuscript explored adolescent risk behaviors in relation to the presence 
and/or development of adolescent depression.  This focused primarily on those behaviors not 
normally associated with the existence of depression, at least not in an adult.  Many symptoms 
are constant between adults and youth, but many are not.  Youth “act-out” in risky behaviors 
much of the time when psychopathology is present.  For example, common behaviors include 
risky sexual behaviors, anger and aggression, and increased conflict with family.  This is 
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partially due to the adolescent continued brain development, hormonal fluctuations, and the 
sense of social and personal identity that is ill defined at this particular time in a person’s life.  
This makes it all the more a priority to correctly identify mental health areas that need to be 
addressed and treated, if indicated.  All of the developmental components of this population 
create an uncertain and unpredictable future, and the path of this future is fluid, at least to a 
certain extent.  It is imperative not to provide suboptimal care; this would be a disservice to their 
future.  
 The final manuscript described results of a descriptive study examining risk behavior 
screening practices using the PARS risk behavior assessment at an adolescent primary care 
health clinic in the southeastern United States.  Several questionable practices related to provider 
fidelity in screening were identified.  The most pressing concern involved the lack of consistent 
screening overall, across all genders, races, ages, and patient presentation.  Lack of completeness 
of the screening instrument was consistent.  Strategies that focus on increasing clinician fidelity 
and consistency regarding depression screening among adolescents have been proposed.  
 Recommendations for improving screening rates in institutions included incorporating a 
brief screening instrument in the waiting area for the patient to fill out prior to being called back 
for examination; increasing public and private school awareness with literature and expert 
speakers; follow-up appointments for a patient with any elevated risk behavior scores, even if not 
in the domain of depression; the addition of other domains on risk screening instruments; and 
various research areas to further identify relationships between risk behaviors and depression.  
 Significant challenges exist in terms of creating and defining regulations, guidelines, best 
practice recommendations, and policy regarding depression screening in the adolescent 
population.  In the first manuscript one of the challenges found was related to the use of 
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alternative treatments over medication (alternative in this context to mean some form of 
psychotherapy or non-medication treatment).  Some of these challenges are associated with 
provider reimbursement, lack of dissemination of research outcomes into practice, and obstacles 
introduced from families.  Part of the training and expertise rooted in a DNP program is the 
ability to shape policy and practice on many levels.  For the particular example of using 
alternative treatments prior to medication in young people, a DNP prepared nurse can help to 
generate changes within communities in regards to this issue, such as taking the lead in creating 
local programs with a primary purpose to offer psychotherapy to young people at a maximally 
reduced cost and that is easily accessible.  Monitoring outcome data from this venture as 
supportive indicators can help a DNP nurse continue to advocate for changes within the 
insurance systems, within federally funded programs, and ultimately to policymakers in order to 
decrease the challenges associated with other treatments over medications as a first-line option.   
 If access to care is a problem due to lack of providers, the DNP clinician can also work 
toward finding avenues that will increase provider availability.  Again, this can be done through 
policy change or through grass roots efforts in a particular region.  Incorporating the input and 
support from other disciplines affected by having insufficient numbers of clinicians to provide 
treatment/care for patients can also contribute strength for change in conjunction with the DNP.  
Much of the responsibility of care in areas underserved by mental health falls on the primary care 
provider.  Therefore, these providers, along with social workers, clinical psychologists, state 
child welfare offices, and others can contribute vital clinical insights when seeking solutions to 
this issue.  Healthcare is shifting to more of a community-based approach, which means that the 
healthcare “team” approach will be the standard model.  The DNP PMH-APRN has the 
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preparation to lead these teams into the most optimal, patient-centered care design that will 
successfully help the patient achieve their highest level of health. 
 All of the suggestions for future research in these manuscripts are areas in which the 
DNP PMH-APRN has a large investment at stake.  Many DNP PMH-APRNs are at the forefront 
of patient care, ensuring the most recent evidence-based information is being accurately reflected 
in practice.  But they also advance the evidence-base related to best practices.  Best practice 
guidelines and recommendation are non-existent without the monitoring and dissemination of 
accurate information generated from well-designed research.  In practice, the DNP provider 
collects and records the pertinent data from patient interactions, analyzing it for areas of potential 
improvement or change, researching for existing information that has addressed this particular 
area, recognizes if a need exists for further investigation, and seeks alternatives to solve the 
clinical problem.  
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Appendix B 
Demographic Collection Form 
 
Date of Review: Date of Service: 
 
 
Medical Record Screening ID #: Medical Record Assigned ID #: 
 
Age: 
 
 
Male        
 
Female         
 
Race/Ethnicity: 
 
County of Residence: 
 
Last Education Grade Completed: 
 
Lives Primarily With (1-parent, 2-parent, 
3-gparent, 4-other family member, 5-other) 
 
Reason for Visit: 
 
Diagnosis: 
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Appendix C 
Data Extraction Form 
 
Domains on PARS PARS included in 
chart 
Risk level 
assessed 
Referral ordered 
BMI    
Weight perception    
Nutrition    
Exercise    
Tobacco use    
Drug use    
Alcohol use    
Sexual activity    
School    
Depression    
Abuse    
Safety    
Violence    
Family relationships and 
Responsibility 
   
Friends and Recreation    
Good qualities and Future 
plans  
   
Immunizations    
 
PARS in chart:  1 = yes; 2 = no 
Risk Level:  0 = N/A; 1 = Low risk; 2 = moderate risk; 3 = High risk 
Referral:  0 = N/A; 1 = yes; 2 = no 
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Appendix D 
Table D1 
 
Demographic Frequencies of Patient, N = 84 
 
 
 
 
 
 
 
 
 
 N % Mean SD 
Age     
   At most recent screening   15.00 1.7 
   At study visit   17.00 1.7 
   Mean time interval between    2.00 1.2 
   % of charts with at least partially 
completed PARS 
    
Gender 
   Male, % 
   Female, % 
 
23 
61 
 
27.4 
72.6 
1.73 0.45 
Race 
   White 
    Black 
    Other 
 
44 
28 
12 
 
52.4 
33.3 
14.3 
1.55 0.68 
Last Grade Completed 
12 
11 
10 
9 
8 
7 
6 
Unknown 
 
21 
14 
15 
12 
2 
5 
1 
14 
 
25.0 
16.7 
17.9 
14.3 
2.4 
6.0 
1.2 
16.7 
 
8.58 4.1 
Lives with 
   One Parent 
   Two Parent 
   Grandparent 
   Other Family Member 
   Unknown 
 
 
35 
26 
5 
2 
2 
 
41.7 
31.0 
6.0 
2.4 
2.4 
2.14 1.47 
Past MH Treatment 
   Males—Yes 
   Males—No 
   Females—Yes 
   Females—No 
 
 
6 
17 
22 
38 
 
7.1 
20.2 
26.2 
45.2 
1.64 0.52 
Referral at Time of Screen 
   Yes 
   No 
 
18 
66 
 
21.4 
78.6 
1.80 0.41 
 
  73 
 
Table D2 
 
PARS Risk Behavior Domains Completion (assessed for low, moderate, or high risk)*  
 
 
% Complete                                                                                                   % / N  
Tobacco Use 100% / 77 
Drug Use 99% / 76 
Alcohol Use 95% / 73 
Abuse 95% / 73 
School 94% / 72 
Safety 94% / 72 
Violence 94% / 72 
Family Relations/Responsibility 94% / 72 
Sexual Activity 91% / 70 
Depression  91% / 70 
Friends and Recreation 91% / 70 
Nutrition 88% / 68 
Exercise 88% / 68  
BMI 78% / 60 
Weight Perception 75% / 58 
Good Qualities and Future Plans 74% / 57 
Immunizations 47% / 36 
*Less the seven charts without a PARS 
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Table D3 
Variables and Association With PARS Performed and/or Referral Made 
 
Screened 
Yes          No  
 
 
Sig (p < .05) 
Referral 
Yes            No  
 
 
Sig (p < .05) 
Gender 
   Male 
   Female 
 
22 
55 
1 
6 
FET .668 
2 
15 
21 
45 
FET .133 
Lives With 
   1 Parent 
   2 Parent 
   Other 
31 
24 
21 
4 
2 
0 
.281 
8 
5 
4 
27 
20 
17 
.934 
Race 
   Caucasian 
   African American 
   Other 
40 
26 
8 
4 
2 
0 
.666 
10 
5 
0 
33 
23 
8 
.300 
       
Table D4 
 
Risk Behavior Domain Counts       
______________________________________________________________________________ 
                              
PARS Item                    Low       Moderate     High              Total  
______________________________________________________________________________ 
                     n             %       n            %            n             %  
 
BMI 
   Males 
   Females 
34 
10 
24 
57a 
 
 
10 
3 
7 
17 
 
16 
6 
10 
27 60 
Weight Perception 
   Males 
   Females 
48 
14 
34 
83 5 
2 
3 
8 5 
0 
5 
8 58 
Nutrition 
   Males 
   Females 
40 
12 
28 
59 17 
4 
13 
25 11 
5 
6 
16 68 
Exercise 
   Males 
   Females 
19 
7 
12 
28 27 
7 
20 
40 22 
6 
16 
32 68 
Tobacco use 
   Males 
   Females 
69 
20 
49 
90 7 
2 
5 
9 1 
0 
1 
1 77 
Drug use 
   Males 
64 
19 
84 9 
1 
12 3 
2 
4 76 
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   Females 45 8 1 
Alcohol use 
   Males 
   Females 
60 
18 
42 
82 11 
2 
9 
15 2 
0 
2 
3 73 
Sexual Activity 
   Males 
   Females 
51 
17 
34 
73 11 
4 
7 
16 8 
0 
8 
11 70 
School 
   Males 
   Females 
55 
14 
41 
76 12 
3 
9 
17 5 
3 
2 
7 72 
Depression 
   Males 
   Females 
48 
14 
34 
69 
 
 
14 
4 
10 
20 8 
3 
5 
11 70 
Abuse 
   Males 
   Females 
61 
17 
44 
84 11 
3 
8 
15 1 
0 
1 
1 73 
Safety 
   Males 
   Females 
66 
18 
48 
92 6 
2 
4 
8 0 
0 
0 
0 72 
Violence 
   Males 
   Females 
68 
18 
50 
94 2 
1 
1 
3 2 
2 
0 
3 72 
Family relationships 
   Males 
   Females 
61 
19 
42 
85 7 
1 
6 
9 4 
1 
3 
6 72 
Friends/recreation 
   Males 
   Females 
60 
18 
42 
86 9 
1 
8 
13 1 
1 
0 
1 70 
Good qualities/future plans 
   Males 
   Females 
50 
14 
36 
88 4 
1 
3 
7 3 
2 
1 
5 57 
*Immunization Domain on PARS not included as the focus was on adolescent behaviors. 
**Figures based upon review of 84 medical records. 
a Percentages may not be 100% accurate due to rounding; percentage was calculated based upon completed domains. 
 
 
 
 
 
 
 
 
  76 
References 
 
Aman, M. G., Hollway, J. A., McDougle, C. J., Scahill, L., Tierney, E., McCracken, J. T., et al. 
(2008). Cognitive effects of risperidone in children with autism and irritable behavior. 
Journal of Child and Adolescent Psychopharmacology, 18(3), 227-236. 
American Academy of Child and Adolescent Psychiatry, Practice Parameter. (2011). Practice 
Parameter for the Use of Atypical Antipsychotic Medications in Children and 
Adolescents. Retrieved from www.aacap.org  
American College of Obstetricians and Gynecologists. (2003). Eating disorders. In: Health Care 
for Adolescents (pp. 83-92). Washington, DC: American College of Obstetricians and 
Gynecologists. 
American College of Preventive Medicine. (2011). Adolescent depression—enhancing outcomes 
in primary care. Retrieved from the American College of Preventive Medicine website:   
http://www.acpm.org/search/all.asp?bst=adolescent+depression 
American College of Preventive Medicine. (2011). Adolescent depression—enhancing outcomes 
in primary care. Retrieved from the American College of Preventive Medicine website:  
http://www.acpm.org/search/all.asp?bst=adolescent+depression 
American Foundation for Suicide Prevention. (2013). Facts and figures. Retrieved from 
http://www.afsp.org/index.cfm?page_id=050CDCA2-C158-FBAC-
16ACCE9DC8B7026C. 
Brendgen, M., Wanner, B., Morin, A. J. S., & Vitaro, F. (2005). Relations with parents and with 
peers, temperament, and trajectories of depressed mood during early adolescence. The 
Journal of Abnormal Child Psychology, 33(5), 579-594. doi: 10.1007/s10802-005-6739-2 
Busch, S. H., & Barry, C. L. (2007). Mental health disorders in childhood: Assessing the burden 
on families. Health affairs 26(4), 1088-1095.  
 
  77 
Carli, V., Hoven, C. W., Wasserman, C., Chiesa, F., Guffanti, G., Sarchiapone, M., Apter, A., 
Balazs, J., et al. (2014). A newly identified group of adolescents at “invisible” risk for 
psychopathology and suicidal behavior: findings from the SEYLE study. World 
Psychiatry, 13(1), 78-86. 
Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health 
Services Administration. (2012). Results from the 2010 National Survey on Drug Use and 
Health: Mental health findings (HHS Publication No. SMA-4667, NSDUH Series H-42). 
Rockville, MD: Substance Abuse and Mental Health Services Administration.  
Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, 
Office of Statistics and Programming. (2012). Retrieved from 
http://www.cdc.gov/healthyyouth/data/index.htm 
Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, 
Office of Statistics and Programming. (2012).  
Chai, G., Mehta, H., Moeny, D., & Governale, L., Office of Surveillance and Epidemiology, 
Center for Drug Evaluation and Research (CDER), Food and Drug Administration 
(FDA). (2013). Atypical antipsychotic drug in the U.S. outpatient pediatric population. 
(Advisory Committees). Silver Spring, MD: FDA. Retrieved from 
www.fda.gov/.../advisorycommittees/committeesmeetingmaterials/pediatricadvisorycom
mittee/ucm272641.pdf 
Chen, D. T., Wynia, M. K., Moloney, R. M., & Alexander, G. C. (2009). U.S. Physician 
knowledge of the FDA-approved indications and evidence base for commonly prescribed 
drugs: results of a national survey. Pharmacoepidemiological Drug Safety, 18, 1094-
1100.  
 
  78 
Christian, R., Saavedra, L., Baynes, B. N., Seitman, B., Wines, R. C. M., Jonas, D. E., et al. 
(2012). Future research needs for first- and second-generation antipsychotics for 
children and young adults (Future research needs paper no. 13). Rockville, MD: Agency 
for Healthcare Research and Quality. Retrieved from 
www.effectivehealthcare.ahrq.gov/reports/final.cfm 
Cohen, D., Bonnot, O., Bodeau, N., Consoli, A., & Laurent, C. (2012). Adverse effects of 
second-generation antipsychotics in children and adolescents: a Bayesian meta- analysis. 
Journal of Clinical Psychopharmacology, 32(3), 309-316. doi: 
10.1097/JCP.0b013e3182549259 
Colorado Department of Health Care Policy and Financing, Colorado Department of Human 
Services. (2013). Psychotropic medication guidelines for children and adolescents in 
Colorado’s child welfare system, solutions for coordinated care. Retrieved from  
www.colorado.gov 
Connell, A.M., & Dishion, T.J. (2008). Reducing depression among at-risk early adolescents: 
Three-year effects of a family-centered intervention embedded within schools. Journal of 
Family Psychology, 22(3), 574-585. 
Correll, C.U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J.M., & Malhotra, A.K. (2009). 
Cardiometabolic risk of second-generation antipsychotic medications during first-time 
use in children and adolescents. JAMA, 302(16), 1765-1773. 
Crowley, M. J., McCrory, D. C., Chatterjee, R., Gierisch, J. M., Myers, E. R., Schmit, K. M., … 
Gillian, D. S. (2014). Prioritization of research addressing antipsychotics for adolescents 
and young adults with bipolar disorder. Annals of Internal Medicine, 160(7), 492-498. 
doi:10.7326/M13-2549 
 
  79 
De Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011). Metabolic 
and endocrine adverse effects of second-generation antipsychotics in children and 
adolescents:  A systematic review of randomized, placebo controlled trials and guidelines 
for clinical practice. European Psychiatry, 26(2011), 144-158.97 
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition TR (2013) American 
Psychiatric Association. 
Dumont, I. P., & Olson, A. L. (2012). Primary care, depression, and anxiety: Exploring somatic 
and emotional predictors of mental health status in adolescents. Journal of the American 
Board of Family Medicine, 25(3), 291-299. doi:10.3122/jabfm.2012.03.110056 
Elsevier, Gold Standard, Inc. (2013) Atypical antipsychotics. Clinical Pharmacology [database 
online]. Retrieved from http://www.clinicalpharmacology.com.  
Findling, R. L., Robb, A., Nyilas, M., Forbes, R. A., Jin, N., Ivanova, S., et al. (2008). A 
multiplecenter, randomized, double blind, placebo-controlled study of oral aripiprazole 
for treatment of adolescents with schizophrenia. American Journal of Psychiatry, 165, 
1432-1441. 
Forman, E.M., & Davies, P.T. (2003). Family instability and young adolescent maladjustment: 
The mediating effects of parenting quality and adolescent appraisals of family security. 
Journal of Clinical Child and Adolescent Psychology, 32, 94-105. 
Fortuna, L., Fulwiler, C., Stone, R. T., Smith, L. M., & Biebel, K. (2008). Disparities in child 
and adolescent psychoactive medication prescription practices by race and ethnicity. 
Center for Mental Health Services Research, University of Massachusetts Medical 
School. 
 
  80 
Fosco, G. M., Caruthers, A. S., & Dishion, T. J. (2012). A six-year predictive test of adolescent 
family relationship quality and effortful control pathways to emerging adult social and 
emotional health. Journal of Family Psychology, 26(4), 565-575. doi: 10.1037/a0028873  
Gould, M., Shaffer, D., & Greenberg, T. (2003). The epidemiology of youth suicide. In R. King 
& A. Apter (Eds.), Suicide in children and adolescents. New York, NY: Cambridge 
University Press. 
Grant, K. E., Compas, B. E., Thurm, A. E., McMahon, S. D., Gipson, P. Y., Campbell, A. J., et 
al. (2006). Stressors and child and adolescent psychopathology: Evidence of moderating 
and mediating effects. Clinical Psychology Review, 26, 257 – 283. 
Haarasilta, L. M., Marttunen, M. J., Kaprio, J. A., & Aro, H. M. (2004). Correlates of depression 
in a representative nationwide sample of adolescents (15-19 years) and young adults (20-
24 years). European Journal of Public Health, 14(3), 280-285. 
Hagan, J. F., Shaw, J. S., Duncan, P. M. (Eds.). (2008). Bright Futures: Guidelines for Health 
Supervision of Infants, Children, and Adolescents, Third Edition. Elk Grove Village, IL: 
American Academy of Pediatrics. 
Harrison, J. N., Cluxton-Keller, F., & Gross, D. (2012). Antipsychotic medication prescribing 
trends in children and adolescents. Journal of Pediatric Health Care, 26(2), 139-145. 
Herres, J. & Kobak, R. (July, 2014). The role of parent, teacher, and peer events in maintaining 
depressive symptoms during early adolescence. Journal of Abnormal Child Psychology, 
1-16 doi: 10.1007/s10802-014-9896-3    
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., 
…Zerniz, G. (2011). AGNP consensus guidelines for therapeutic drug monitoring in 
psychiatry: Update 2011. Pharmacopsychiatry, 44(06), 195-235. Retrieved from 
http://dx.doi.org/10.1055/s-0031-1286287 
 
  81 
Huang, G. C., Unger, J. B., Soto, D., Fujimoto, K., Pentz, M. A., Jordan-Marsh, M., & Valente, 
T. W. (2013). Peer influences: the impact of online and offline friendship networks on 
adolescent smoking and alcohol use. Journal of Adolescent Health, 54(5), 508-514. 
Retrieved from http://www.jahonline.org/article/S1054-139X(13)00366-2/ 
Institute of Medicine (US) and National Research Council (US) Committee on the Science of 
Adolescence. (2011). The science of adolescent risk-taking: workshop report. The 
influence of environment (5). Washington (DC): National Academies Press. Retrieved 
from: http://www.ncbi.nlm.nih.gov/books/NBK53409/ 
Irwin, C. E., Jr, Adams, S. H., Park, M. J., & Newacheck, P. W. (2009). Preventive care for 
adolescents: Few get visits and fewer get services. Pediatrics, 123, e565-e572.  
James, A. C. (2010). Prescribing antipsychotics for children and adolescents. Advances in 
Psychiatric Treatment, 16, 63-75. doi: 10.1192/apt.bp.108.005652 
Kennebeck, S., & Bonin, L. (2015, February). Suicidal behavior in children and adolescents: 
Epidemiology and risk factors. Retrieved from Wolters Kluwer Health UpToDate 
website:  http://www.uptodate.com/contents/suicidal-behavior-in-children-and-
adolescents-epidemiology-and-risk-factors 
Khan, M. R., Kaufman, J. S., Pence, B. W., Gaynes, B. N., Adimora, A. A., Weir, S. S., & 
Miller, W. C. (2009). Depression, sexually transmitted infection, and sexual risk behavior 
among young adults in the United States. Archives of Pediatric & Adolescent Medicine, 
163(7), 644-652. doi: 10.1001/archpediatrics.2009.95. 
Khan, M. R., Kaufman, J. S., Pence, B. W., Gaynes, B. N., Adimora, A. A., Weir, S. S., & 
Miller, W. C. (2009). Depression, sexually transmitted infection, and sexual risk behavior 
among young adults in the United States. Archives of Pediatric & Adolescent Medicine, 
163(7), 644-652. doi: 10.1001/archpediatrics.2009.95. 
 
  82 
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., 
… Hsiao, J. K. (2005). The clinical antipsychotic trials of intervention effectiveness 
(CATIE) investigators: Effectiveness of antipsychotic drugs in patients with chronic 
schizophrenia. New England Journal of Medicine, 353, 1209-1223 
Luebbe, A. M., Bell, D. J., Allwood, M. A., Swenson, L. P., & Early, M. C. (2010). Social 
information processing in children: specific relations to anxiety, depression, and affect. 
Journal of Clinical Child & Adolescent Psychology, 39(3), 386-399. 
Maurer, D. M. (2012). Screening for depression. American Family Physician, 85(2), 139-144. 
Retrieved from www.aafp.org/afp 
Medicaid Medical Directors Learning Network and Rutgers Center for Education and Research 
on Mental Health Therapeutics. (2010). Antipsychotic medication use in Medicaid 
children and adolescents: Report and resource guide from a 16-state study 
(MMDLN/Rutgers CERTs Report No. 1). Retrieved from 
http://rci.rutgers.edu/~cseap/MMDLNAPKIDS.html. 
Merriam-Webster online Dictionary (2015, January 22). Definition of deviant. Retrieved from 
http://www.merriam-webster.com/dictionary/deviant 
Michaud, C. M., McKenna, M. T., Begg, S., Tomijima, N., Majmudar, M., Bulzacchelli, M. T., 
… Murray, C. JL. (2006). The burden of disease and injury in the United States 1996. 
Population Health Metrics, 4(11). doi: 10.1186/1478-7954-4-11 
Michigan Quality Improvement Consortium. (2015). Retrieved from 
http://www.mqic.com/physician-tools.htm 
National Institute of Mental Health (NIMH). (2011). Teen brain: Still under construction (NIH 
Publication No. 11-4929). Retrieved from 
 
  83 
http://www.nimh.nih.gov/health/publications/the-teen-brain-still-under-
construction/index.shtml 
Nielsen, R. E., Laursen, M. F., Vernal, D. L., Bisgaard, C., Jakobsen, H., Steinhausen, H. C., & 
Correll, C. U. (2014). Risk of diabetes in children and adolescents exposed to 
antipsychotics: A nationwide 12-year case-control study. Journal of the American 
Academy of Child & Adolescent Psychiatry, 53(9), 971-979. doi: 
10.1016/j.jaac.2014.04.023 
Olfson, M., Blanco, C., Liu, L., Moreno, C., & Gonzalo, L. (2006). National trends in the 
outpatient treatment of children and adolescents with antipsychotic drugs. Archives of 
General Psychiatry, 63,679-685. 
Olfson, M., Blanco, C., Liu, S. M., Wang, S., & Correll, C. U. (2012). National trends in the 
office-based treatment of children, adolescents, and adults with antipsychotics. Archives 
of General Psychiatry, 69(12), 1247-1256. 
Olfson, M., Crystal, S., Huang, C., & Gerhard, T. (2010). Trends in antipsychotic drug use by 
very young, privately insured children. The Journal of the American Academy of Child 
and Adolescent Psychiatry, 49(1), 13-23. 
Olson, A. L., Kelleher, K. J., Kemper, K. J., Zuckerman, B. S., Hammond, C. S., & Dietrick, A. 
J. (2001). Primary care pediatricians’ roles and perceived responsibilities in the 
identification and management of depression in children and adolescents. Ambulatory 
Pediatrics, 1, 91-98. 
Panagiotopoulos, C., Ronsley, R., Elbe, D., Davidson, J., & Smith, D. H. (2010). First do no 
harm: Promoting an evidence-based approach to atypical antipsychotic use in children 
and adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 
12(2), 124-137. 
 
  84 
Pandina, G. J., Bossie, C. A., Youssef, E., Zhu, Y., & Dunbar, F. (2007). Risperidone improves 
behavioral symptoms in children with autism in a randomized, double-blind, placebo-
controlled trial. Journal of Autism and Developmental Disorders, 37(2), 367-373. 
Pathak, P., West, D., Martin, B. C., Helm, M. E., & Henderson, C. (2010). Evidence-based use 
of second-generation antipsychotics in a state Medicaid pediatric population, 2001—
2005. Psychiatric Services, 61, 123—129.  
Penfold, R. B., Stewart, C., Hunkeler, W. M., Madden, J. M., Cummings, J., Owen-Smith, A. A.,   
Simon, G. E. (2013). Use of antipsychotic medications in pediatric populations: What do 
the data say? Current Psychiatry Report, 15(2), 426. doi: 10.1007/s11920-013-0426-8 
Primack, B. A., Swanter, B., Georgiopoulos, A. M., Land, S. R., & Fine, M. J. (2009). 
Association between media use in adolescence and depression in young adulthood. 
Archives of General Psychiatry, 66(2), 181-188. Retrieved from 
http://archpsyc.jamnetwork.com/ 
Respress, B. N., Morris, D. L., Lewin, L. C., & Francis, S. A. (2013). Social determinants of 
adolescent depression: an examination of racial differences. Issues in Mental Health 
Nursing, 34, 539-549. doi: 10.3109/01612840.2012.758206 
Rettew, D. C., Greenblatt, J., Kamon, J., Neal, D., Harder, V., Wasserman, R., … McMains, W. 
(2015). Antipsychotic medication prescribing in children enrolled in Medicaid. 
Pediatrics, 135(4), 658-665. doi: 10.1542/peds.2014-2260  
Richmond, M. J., Mermelstein, R. J., & Metzger, A. (2012). Heterogeneous friendship 
affiliation, problem behaviors, and emotional outcomes among high-risk adolescents. 
Prevention Science, 13, 267-277. doi:10.1007/s11121-011-0261-2 
Rockhill, C. M., Katon, W., Richards, J., McCauley, E., McCarty, C. A., Myaing, M. T., et al. 
(2013). What clinical differences distinguish depressed teens with and without comorbid 
 
  85 
externalizing problems? General Hospital Psychiatry, 35(4), 444-447. 
doi:10.1016/j.genhosppsych.2013.01.002 
Rood, L., Roelofs, J., Bogels, S. M., & Meesters, C. Stress-reactive rumination, negative 
cognitive style, and stressors in relationship to depressive symptoms in non-clinical 
youth. Journal of Youth and Adolescence, 41, 414-425. doi:10.1007/s10964-011-9657-3 
Rouse, C. E. (2005, September).  The labor market consequences of an inadequate education, 
(Executive Summary).  
Rubin, A. G., & Primack, B. A. (2009). Associations between depressive symptoms and sexual 
risk behavior in a diverse sample of female adolescents. Journal of Pediatric & 
Adolescent Gynecology, 22, 306-312. doi: 10.1016/j.jpag.2008.12.011 
Rubin, A. G., & Primack, B. A. (2009). Associations between depressive symptoms and sexual 
risk behavior in a diverse sample of female adolescents. Journal of Pediatric & 
Adolescent Gynecology, 22, 306-312. doi: 10.1016/j.jpag.2008.12.011 
Salerno, J., & Barnhart, S. (2014). Evaluation of RAAPS risk screening tool for used in detecting 
adolescents with depression. Journal of Child and Adolescent Psychiatric Nursing, 27(1), 
20-25. doi: 10.1111/jcap.12060 
Seeley, J. R., Stice, E., & Rohde, P. (2009). Screening for depression prevention: Identifying 
adolescent girls at high risk for future depression. The Journal of Abnormal Psychology, 
118(1), 161-170. doi: 10.1037/a0014741 
Seeley, J. R., Stice, E., & Rohde, P. (2009). Screening for depression prevention: Identifying 
adolescent girls at high risk for future depression. The Journal of Abnormal Psychology, 
118(1), 161-170. doi: 10.1037/a0014741 
Seida, J. C., et al. (2012). Antipsychotics for children and young adults: a comparative 
effectiveness review. Pediatrics, 129(3), e771-e784. doi: 10.1542/peds.2011-2158 
 
  86 
Sokal, J., Messias, E., Dickerson, F. B., Kreyenbuhl, J., Brown, C. H., Goldberg, R. W., & 
Dixon, L. B. (2004). Comorbidity of medical illnesses among adults with serious mental 
illness who are receiving community psychiatric services. Journal of Nervous Mental 
Disorders, 192, 421-427 
The National Institute for Health Care Management. (2010, February). Improving early 
identification & treatment of adolescent depression: Considerations & strategies for 
health plans. Washington, DC: NIHCM Foundation. 
The National Research Council and the Institute of Medicine of the National Academies. (2009). 
Preventing mental, emotional, and behavioral disorders among young people: Progress 
and possibilities. Washing, DC: The National Academies Press.   
U.S. Agency for Healthcare Research and Quality. (2011). Off-label use of atypical 
antipsychotics: An update (Comparative Effectiveness Reviews, No. 43). Retrieved from: 
http://www.ncbi.nlm.nih.gov/books/NBK66081/ 
U.S. Department of Health and Human Services (HHS), Office of the Surgeon General and 
National Action Alliance for Suicide Prevention. (2012). National Strategy for Suicide 
Prevention: Goals and Objectives for Action. Washington, DC: HHS. 
U.S. Department of Health and Human Services (HHS), Office of the Surgeon General and 
National Action Alliance for Suicide Prevention. (2012). 2012 National strategy for 
suicide prevention: Goals and objective for action. Retrieved from 
http://www.surgeongeneral.gov/library/reports/national-strategy-suicide-
prevention/index.html 
U.S. Department of Health and Human Services. Agency for Healthcare Research and Quality, 
Centers for Medicaid &Medicare Services. (2013). Atypical Antipsychotic Medications: 
Use in Pediatric Patients. Retrieved from http://www.cms.gov/Medicare-Medicaid-
 
  87 
Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-
Materials/Downloads/atyp-antipsych-pediatric-factsheet.pdf 
U.S. Preventive Services Task Force. (2009). Screening and treatment for major depressive 
disorder in children and adolescents: U.S. preventive services task force recommendation 
statement. Pediatrics, 123,1223-1228. Retrieved from 
http://www.uspreventiveservicestaskforce.org/uspstf09/depression/chdeprrs.htm 
Waller, M. W., Hallfors, D. D., Halpern, C. T., Iritani, B. J., Ford, C. A., & Guo, G. (2006). 
Gender differences in associations between depressive symptoms and patterns of 
substance use and risky sexual behavior among a nationally representative sample of U.S. 
adolescents. Archives of Women’s Mental Health 9, 139–150. doi 10.1007/s00737-006-
0121-4 
Waller, M. W., Hallfors, D. D., Halpern, C. T., Iritani, B. J., Ford, C. A., & Guo, G. (2006). 
Gender differences in associations between depressive symptoms and patterns of 
substance use and risky sexual behavior among a nationally representative sample of U.S. 
adolescents. Archives of Women’s Mental Health 9, 139–150. doi 10.1007/s00737-006-
0121-4 
Williams, S. B., O'Connor, E., Eder, M., & Whitlock, E. (2009). Screening for child and 
adolescent depression in primary care settings: a systematic evidence review for the US 
Preventive Services Task Force. Pediatrics, 123(4), e716. 
Yaroslavsky, I., Pettit, J. W., Lewinsohn, P. M., Seeley, J. R., & Roberts, R. E. (2013). 
Heterogeneous trajectories of depressive symptoms: Adolescent predictors and adult 
outcomes. Journal of Affective Disorders, 1 48, 391-399. doi:10.1016/j.jad.2012.06 
Young, J. F., Miller, M. R., & Khan, N. (2010). Screening and managing depression in 
adolescents. Adolescent health, medicine, and therapeutics, 1, 87-95. 
 
  88 
Zito, J. M., Burcu, M., Ibe, A., Safer, D. J., & Magder, L. S. (2013). Antipsychotic use by 
Medicaid-insured youths: Impact of eligibility and psychiatric diagnosis across a decade. 
Psychiatric Services, 64(3), 223-229.  
 
 
